MD Newsline

In this episode of MD Newsline, Dr Frederick Howard, breast oncologist at the University of Chicago and leader of a research group focused on AI-driven biomarker development, explores the rapidly evolving role of artificial intelligence in breast cancer care. Dr. Howard provides a comprehensive overview of how AI is being integrated into oncology—from radiographic imaging and digital pathology to clinical decision support and language models. He discusses both the promise and the practical challenges of deploying AI tools in real-world workflows, including validation standards, regulatory guardrails, and ethical considerations. The conversation also dives into emerging applications such as AI-based HER2 quantification, recurrence risk prediction from H&E slides, and the potential for multimodal models to transform precision medicine. Episode Highlights: AI in Radiology and Mammography Dr. Howard explains the evolution from early computer-aided detection systems to modern deep learning algorithms trained on millions of mammograms. He discusses emerging AI-driven breast cancer risk prediction tools derived directly from imaging and how they may enhance early detection strategies. Digital Pathology and Biomarker Development AI tools are increasingly capable of quantifying immunohistochemistry and identifying features beyond human visual interpretation. Dr. Howard highlights research presented at major oncology meetings demonstrating improved concordance in HER2-low classification and improved reproducibility in biomarker scoring. Predicting Recurrence Risk Without Genomic Testing One of the most promising areas involves AI models trained on H&E slides to predict recurrence risk—potentially matching or exceeding established genomic assays such as Oncotype DX and MammaPrint. Dr. Howard discusses the validation challenges required before these tools can replace or complement genomic testing in clinical practice. HER2-Low Classification and Antibody-Drug Conjugates The discussion explores limitations of traditional HER2 immunohistochemistry, especially at the lower end of expression. AI-based quantitative approaches may improve patient stratification for HER2-directed antibody-drug conjugates, though questions remain about predictive thresholds and biological mechanisms. Language Models in Oncology Practice Dr. Howard examines the growing use of large language models for literature review, documentation support, and clinical trial matching. He emphasizes the need for HIPAA-compliant systems, clinician oversight, and standardized evaluation frameworks to ensure safe and responsible deployment. Ethics, Governance, and Over-Reliance From data privacy to clinical accountability, the episode addresses the ethical considerations surrounding AI in cancer care. Dr. Howard cautions against over-reliance on AI systems and underscores the importance of maintaining clinician expertise and critical thinking. The Future: Multimodal AI and Precision Medicine Looking ahead, Dr. Howard envisions a future where digital pathology, genomics, imaging, and clinical data converge into multimodal AI systems capable of delivering truly personalized treatment recommendations. He stresses that large-scale data sharing and collaboration will be essential to realizing this potential. Key Takeaway Artificial intelligence is no longer theoretical in oncology—it is actively shaping diagnostics, risk stratification, and treatment selection in breast cancer. However, rigorous validation, ethical governance, and thoughtful integration into clinical workflows are critical to ensuring that AI enhances—rather than replaces—expert clinical judgment. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Frederick Howard: Here

In this episode of MD Newsline, Dr. Janeane N. Anderson, Assistant Professor at the University of Tennessee Health Science Center and breast cancer researcher, shares insights from the ACCESS Study—an innovative qualitative research initiative focused on understanding why Black women in the Mid-South region are disproportionately diagnosed with advanced-stage breast cancer. Dr. Anderson discusses structural barriers, community-based recruitment strategies, and the importance of centering lived experiences in oncology research. She also highlights the critical need for equitable research participation, race- and gender-concordant research teams, and stronger clinician engagement to improve outcomes for underserved populations. Episode Highlights: Understanding Advanced-Stage Breast Cancer in the Mid-South Dr. Anderson explains how the Mississippi Delta region represents a "cancer hotspot," with higher rates of late-stage diagnoses and mortality among Black women. She explores how structural vulnerability, transportation challenges, cultural norms, and fragmented healthcare systems contribute to disparities. The ACCESS Study: A Community-Centered Research Design The ACCESS Study is a three-year qualitative investigation examining socio-ecological factors that increase the likelihood of de novo metastatic breast cancer diagnoses among Black women. Dr. Anderson outlines her multi-method approach, including: ·        In-depth interviews with photo elicitation ·        Ethnographic "go-alongs" in participants' neighborhoods ·        Observations during clinic visits ·        Interviews with regional clinicians This immersive methodology allows researchers to understand not just clinical outcomes, but the lived realities shaping patient journeys. Barriers to Recruitment and Participation Recruiting women with metastatic breast cancer presents unique challenges. Dr. Anderson discusses barriers such as: ·        Health status and treatment burden ·        Caregiving responsibilities ·        Transportation and rural geography ·        Income instability and housing challenges ·        Research mistrust rooted in sociohistorical and contemporary inequities She emphasizes that participation barriers are often structural—not a lack of interest. Recruitment Strategies That Worked Dr. Anderson highlights the importance of race- and gender-concordant research teams, which foster trust and cultural understanding. Additional effective strategies included: ·        Leveraging electronic health records for efficient identification ·        Community-based outreach in churches, libraries, salons, and local organizations ·        Multiple consent touchpoints to address concerns and build rapport Her key message to clinicians: Ask. Many eligible patients are interested in research—but are never invited. Moving Beyond Accrual Metrics Dr. Anderson argues that equitable research should not be measured by numbers alone. Individual stories—"n of 1" experiences—reveal intersectional traumas and systemic barriers that large datasets may overlook. She advocates for qualitative methodologies to better understand the "why" behind disparities. Sexual Health and Survivorship At the San Antonio Breast Cancer Symposium, Dr. Anderson also noted the need for greater focus on oncosexology. Sexual health remains one of the most unmet needs in breast cancer survivorship, impacting quality of life, adherence, and overall well-being. Key Takeaway Dr. Anderson underscores that addressing disparities in advanced breast cancer requires more than clinical innovation. It demands community engagement, culturally concordant research teams, clinician advocacy, and methodologies that center the lived experiences of Black women. True equity begins with listening—and asking.  Resource Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Janeane N. Anderson: Here

In this episode of MD Newsline, Dr. Jordonna Brown, a medical oncologist at Kings County Hospital in New York City, shares her frontline experience caring for patients in a safety-net hospital setting. Speaking from the San Antonio Breast Cancer Symposium (SABCS), Dr. Brown discusses cancer disparities, late-stage presentation, mistrust in the healthcare system, and the evolving landscape of breast cancer treatment. She offers a candid look at the social determinants of health shaping patient outcomes—from delayed screening and misconceptions about chemotherapy to barriers in long-term adherence and clinical trial participation. Episode Highlights: Late-Stage Presentation and Screening Gaps Dr. Brown highlights a concerning trend: many patients present with advanced-stage breast cancer due to missed routine mammograms. Barriers include misconceptions about radiation exposure, fear of pain, religious beliefs, and lack of awareness about updated screening guidelines starting at age 40. Mistrust and Chemotherapy Misconceptions One of the most persistent challenges is distrust in the medical system. Patients often fear that chemotherapy may be more harmful than beneficial. Dr. Brown emphasizes the importance of patient-centered communication, empathy, and transparent education to build trust and empower informed decisions. Younger Patients and Aggressive Disease Breast and colon cancers are increasingly diagnosed in younger populations. In women under 40, breast cancer often demonstrates more aggressive tumor biology. Younger patients also face unique psychosocial challenges, including body image concerns, fertility considerations, career disruptions, and adherence to long-term maintenance therapy. Socioeconomic Barriers and Access to Care Financial instability, employment loss, transportation issues, and food insecurity can significantly impact adherence and long-term outcomes. Dr. Brown discusses how institutional support—such as social services, transportation programs, counseling, and food banks—helps mitigate these barriers. Clinical Trials and Underrepresentation Dr. Brown notes persistent skepticism around clinical trials among underrepresented communities. She underscores the need for improved education, emphasizing that today's standard treatments are the result of prior clinical trials—and that participation advances care for future generations. Emerging Therapies and Personalized Medicine At SABCS, Dr. Brown was encouraged by advances in early-stage hormone-positive breast cancer, including new selective estrogen receptor degraders (SERDs) such as giredestrant, which may offer improved tolerability compared to traditional endocrine therapies. She also discusses the growing role of artificial intelligence in shaping cancer care and the importance of ensuring diverse data representation in AI-driven tools. Mental Health and Survivorship The emotional and social impact of a cancer diagnosis often extends beyond treatment. Family dynamics, job security, and mental health are frequently under-addressed areas. Dr. Brown advocates for integrated palliative care, psychotherapy services, and survivorship groups to support patients holistically.   Key Takeaway Addressing breast cancer disparities requires more than medical innovation—it demands trust-building, education, equitable access, and culturally sensitive communication. By partnering with patients, improving representation in clinical research, and strengthening community-based support systems, clinicians can meaningfully improve outcomes across diverse populations.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Jordonna  Brown: Here

In this episode of MD Newsline, Dr. Theodoros Karantanos, Assistant Professor of Medical Oncology at the Johns Hopkins University Sidney Kimmel Cancer Center, discusses the emerging role of inflammatory signaling in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Karantanos shares insights from his laboratory research exploring how inflammatory pathways—particularly interferon gamma and JAK-STAT signaling—contribute to treatment resistance, including resistance to venetoclax. He also highlights the impact of TP53 mutations, bone marrow microenvironment dynamics, and post-translational modifications in shaping disease progression and therapeutic response. Episode Highlights: Inflammatory Signaling and Venetoclax Resistance High-risk MDS and AML frequently demonstrate upregulation of inflammatory pathways. Dr. Karantanos explains how interferon gamma signaling activates the JAK-STAT cascade (JAK1/2, STAT1/3/5), leading to transcriptional programs associated with resistance to venetoclax and chemotherapy. The Role of TP53 in Driving Inflammation Loss of TP53 function not only impairs apoptosis but may intrinsically upregulate interferon gamma signaling within leukemic cells. This cell-intrinsic inflammatory activation may partially explain why TP53-mutated MDS and AML remain particularly difficult to treat. Post-Translational Modifications as Resistance Drivers Phosphorylation and ubiquitination play central roles in regulating inflammatory cascades. Dr. Karantanos emphasizes that proteomic and phospho-signature analyses are essential, as RNA expression alone cannot fully capture pathway activation under therapeutic pressure. Bone Marrow Microenvironment and Cytokine Crosstalk The bone marrow niche—including fibroblasts, adipocytes, endothelial cells, and immune subsets—contributes to resistance through cytokine secretion (e.g., IL-1β, TNF-α) and drug metabolism. These interactions reshape therapeutic exposure and promote survival of malignant clones. Monocytic Leukemias and Inflammatory Activation Monocytic AML subtypes (M4/M5) appear particularly enriched in inflammatory signaling, including interferon gamma and TNF-α activation. These subsets may represent high-priority targets for inflammation-modulating strategies. Targeting Inflammatory Pathways: Translational Strategies Potential therapeutic approaches include IRAK1/IRAK4 inhibitors, JAK pathway modulation, and antibody-drug conjugates targeting downstream interferon-regulated surface proteins such as CCRL2 and ICAM-1. Combination and triplet regimens may offer future improvements over venetoclax-based standards. Single-Cell and Spatial Transcriptomics Dr. Karantanos highlights the importance of computational biology, single-cell RNA sequencing, and spatial transcriptomics in deciphering the complex inflammatory networks within the bone marrow microenvironment. These technologies are critical for identifying actionable nodes and refining patient stratification. Key Takeaway Inflammatory signaling is not merely a bystander in myeloid neoplasms—it is a central driver of disease evolution and therapeutic resistance. Integrating inflammatory biomarkers, post-translational pathway profiling, and microenvironmental analysis may unlock new precision strategies for high-risk MDS and AML, particularly in TP53-mutated and monocytic subtypes where unmet need remains greatest. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact With Dr. Theodoros Karantanos: Here

In this episode of MD Newsline, Dr. Marco Ruella, Associate Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, joins us from the American Society of Hematology (ASH) meeting to discuss a paradigm-shifting topic: host factors in cancer immunotherapy. Dr. Ruella explores how biological sex, aging, chronic inflammation, obesity, exercise, and the microbiome influence responses to therapies such as checkpoint inhibitors and CAR T-cell therapy. The conversation highlights emerging data, translational research, and the growing need to capture holistic patient information to optimize outcomes. Episode Highlights: Why Host Factors Matter in Immunotherapy Traditional clinical trials focus heavily on tumor biology, but host characteristics—including sex, age, metabolic state, and lifestyle—also shape immune responsiveness. Dr. Ruella explains how incorporating these variables can help explain why only a subset of patients achieve durable benefit. Sex-Based Differences in Immune Response Research suggests meaningful biological differences in cancer incidence, immune activation, and treatment outcomes between males and females. Female patients often demonstrate a more "inflamed" or "hot" tumor microenvironment, potentially contributing to stronger immune responses. Hormonal influences, X-linked immune genes, and lifestyle factors may all contribute. Chronic vs. Acute Inflammation Inflammation is a double-edged sword. While acute inflammation after therapy can enhance anti-tumor effects, chronic baseline inflammation is associated with poorer outcomes and greater toxicity in CAR T-cell therapy. Biomarkers such as ferritin, IL-6, CRP, and ESR may help stratify risk. Aging and Biological Fitness Chronological age alone does not predict immunotherapy outcomes. Instead, biological fitness and muscle mass (sarcopenia) may be more relevant predictors of response and toxicity. Emerging research aims to better define "biological age" to guide treatment decisions. Microbiome, Diet, and Metabolism Dr. Ruella shares compelling data linking gut microbiome diversity to CAR T-cell efficacy. Antibiotic exposure before therapy has been associated with poorer outcomes. Additionally, ketogenic diets and ketone bodies such as beta-hydroxybutyrate are being explored to enhance T-cell function in clinical trials. Exercise as an Immune Modulator Short-term exercise can mobilize NK cells and T cells into circulation, potentially priming the immune system before immunotherapy. Ongoing trials are investigating whether structured exercise programs may improve treatment efficacy. AI, Wearables, and the Future of Data Capture To fully understand host factors, clinicians must systematically collect data on diet, exercise, sleep, and inflammation. Wearables, mobile applications, and artificial intelligence may enable more comprehensive, multi-omic profiling and personalized immunotherapy strategies. Key Takeaway Cancer immunotherapy is not determined solely by tumor biology—it is profoundly shaped by the host. Sex differences, chronic inflammation, metabolic health, and lifestyle factors all influence immune function and treatment response. Integrating these variables into clinical research and real-world practice may unlock more precise, equitable, and effective immunotherapy strategies.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr Marco Ruella: Here

In this episode of MD Newsline,  Dr. Dejah Blake, a fifth-year PhD candidate at Emory University, joins us from the American Society of Hematology (ASH) conference to discuss the rapidly evolving landscape of CAR T-cell therapy. Dejah shares insights into engineering next-generation CAR T cells, improving accessibility through in vivo manufacturing, and addressing diversity gaps in clinical research. From armored CARs to gene editing and humanized mouse models, this conversation explores how innovation and equity must move forward together in advancing cancer immunotherapy. Episode Highlights: In Vivo CAR T Cells and Accessibility Traditional CAR T-cell therapy is often described as a "boutique" treatment—highly personalized and complex to manufacture. Dejah explains how in vivo CAR T strategies, including viral vectors and gene-editing approaches, could offer more accessible, potentially off-the-shelf options. Reducing manufacturing time and cost may significantly expand patient access. Gene Editing and the Next Frontier Gene editing technologies are reshaping how scientists design immune cells. Dejah discusses how advances in vector engineering, nanoparticles, and genome modification are transforming the field—not just for cancer, but for broader therapeutic applications. Armored CAR T Cells and Micro-Pharmacies Armored CAR T cells—engineered to secrete cytokines or other immune-modulating factors—represent an exciting innovation. These enhanced cells may help overcome tumor heterogeneity, antigen escape, and hostile tumor microenvironments, particularly in solid tumors. Persistence and the Tumor Microenvironment One of the biggest challenges in CAR T-cell therapy is ensuring persistence in immunosuppressive tumor environments. The discussion explores strategies to generate stem cell–like CAR T cells, balance memory and effector functions, and resist chronic antigen stimulation. Preclinical Models and Translational Science Dejah explains the importance—and limitations—of mouse models, including humanized and patient-derived xenograft (PDX) systems. While essential for mechanistic insight, these models do not always predict first-in-human outcomes, underscoring the need for thoughtful translational design. Retrospective Data, AI, and Clinical Blind Spots As more patients receive CAR T therapy, retrospective analyses are revealing patterns in durability, toxicity, and response. The conversation also addresses data blind spots—particularly regarding racial, socioeconomic, and age diversity—and emphasizes the importance of equitable representation in clinical research. Bridging Bench to Bedside Dejah highlights the growing collaboration between academia and industry in advancing cell therapy. Funding models, clinician-researcher partnerships, and patient-centered translational thinking are essential to moving discoveries from laboratory to clinic responsibly. Key Takeaway The future of CAR T-cell therapy depends not only on technological innovation—such as gene editing and in vivo engineering—but also on accessibility, diversity, and translational collaboration. By combining scientific rigor with equity-focused research, the next generation of immunotherapy can become more effective, scalable, and inclusive.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Dejah Blake: Here

In this episode of MD Newsline, behavioral scientist  Dr. Josh Klapow, registered dietitian Kim Shapira, and health advocate Sishman Rimpson explore the powerful connection between psychology, nutrition, and long-term health outcomes. Together, they unpack how behavioral patterns, mindset, and sustainable lifestyle changes influence chronic disease prevention and patient adherence. The discussion highlights the real-world challenges patients face when attempting to modify diet, physical activity, and stress management—and how healthcare professionals can better support lasting change through practical, evidence-based strategies. Episode Highlights: The Role of Behavioral Psychology in Healthcare Dr. Klapow explains how behavioral science plays a foundational role in chronic disease prevention and management. He discusses why knowledge alone does not change behavior and how emotional drivers, habit formation, and environmental cues shape patient decisions. Nutrition as a Sustainable Lifestyle, Not a Short-Term Fix Kim Shapira emphasizes the importance of shifting from restrictive dieting to sustainable eating patterns. She outlines practical approaches to portion awareness, mindful eating, and building a healthy relationship with food—strategies that promote long-term success rather than temporary results. Patient Adherence and Motivation The panel discusses common barriers to adherence, including stress, misinformation, unrealistic expectations, and social pressures. They explore how clinicians can foster accountability while maintaining empathy and realistic goal-setting. Bridging Mental and Physical Health Sishman Rimpson highlights the importance of integrating mental health awareness into routine medical care. Addressing stress, sleep, and emotional well-being can significantly enhance patient engagement and treatment outcomes. Preventive Care and Community Impact The conversation also explores how preventive strategies—when implemented at both individual and community levels—can reduce the burden of chronic diseases such as obesity, diabetes, and cardiovascular disease. Key Takeaway Sustainable health outcomes require more than prescriptions—they demand behavioral insight, patient-centered communication, and collaborative care. By integrating psychology, nutrition science, and practical lifestyle strategies, healthcare professionals can empower patients to make meaningful, lasting changes. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with panelist: ·       Josh Klapow: Here ·       Kim Shapira: Here ·       Sishman Rimpson: Here

In this episode of MD Newsline, Dr. Amber Johnson, Assistant Professor of Medicine and General Cardiologist at the University of Chicago, provides an in-depth look at modern cholesterol management and cardiovascular risk reduction. She discusses evolving lipid guidelines, aggressive LDL-C targets, statin intolerance, and the growing role of non-statin therapies. Dr. Johnson also explores emerging research on lipoprotein(a), hypertriglyceridemia, and future directions in lipid-lowering treatment. Episode Highlights Evolving Cholesterol Management and ASCVD Risk Dr. Johnson explains how cholesterol treatment has become more aggressive over the past decade, driven by robust evidence linking LDL cholesterol to cardiovascular events. She emphasizes LDL-C as the primary treatment target and discusses the role of HDL, triglycerides, and inflammatory markers such as high-sensitivity CRP, particularly in women. Lifestyle Modification and Population-Level Prevention Heart-healthy lifestyle interventions remain foundational to cardiovascular prevention. Dr. Johnson highlights the American Heart Association's Life's Essential Eight, including physical activity, diet, sleep, and smoking cessation, as critical components of long-term risk reduction. Key Updates in 2025 Dyslipidemia Guidelines Dr. Johnson reviews the 2025 ESC/EAS-focused update, emphasizing lower LDL-C targets for high- and extreme-risk patients. She discusses the increasing use of PCSK9 inhibitors, adjunct lipid-lowering therapies, and the recommendation for routine lipoprotein(a) screening as a risk-modifying factor. Risk Assessment and Personalized Treatment Decisions For primary prevention patients, Dr. Johnson outlines how risk calculators, coronary artery calcium scoring, and comorbidities such as diabetes and metabolic syndrome guide lipid-lowering intensity. She also addresses how updated endocrine and diabetes guidelines influence earlier and more aggressive treatment strategies. Statin Intolerance and Treatment Sequencing Persistent barriers to statin use include side effect concerns, cost, and polypharmacy. Dr. Johnson shares practical strategies for managing statin intolerance, including dose adjustments, switching statins, alternate-day dosing, and the addition of non-statin therapies such as ezetimibe, bempedoic acid, and PCSK9 inhibitors. Non-Statin Therapies and New Treatment Options Dr. Johnson discusses when to escalate therapy to PCSK9 inhibitors, including monoclonal antibodies and siRNA-based agents like inclisiran. She also explains how cost, access, and insurance coverage influence real-world treatment decisions. Triglycerides and Emerging Lipid Targets While triglycerides are often overlooked, Dr. Johnson reviews their clinical significance, particularly in severe hypertriglyceridemia. She discusses lifestyle interventions, fibrates, omega-3 therapies, and emerging agents targeting ANGPTL3 and APOC-3. The Role of Lipoprotein(a) Routine Lp(a) screening is gaining momentum due to its strong association with cardiovascular disease and aortic stenosis. Dr. Johnson reviews current guideline recommendations, clinical utility, and ongoing outcome trials such as OCEAN and HORIZON that may soon reshape treatment options. Special Populations and Complex Care Dr. Johnson addresses lipid management in patients with chronic kidney disease, HIV, inflammatory diseases, and cancer, emphasizing individualized therapy and careful consideration of drug–drug interactions. Future Directions in Lipid Therapy Looking ahead, Dr. Johnson explores long-acting therapies and gene-editing approaches such as CRISPR, while highlighting the importance of health equity, access to care, and sustainable lifestyle interventions. Key Takeaway Dr. Johnson underscores that lower LDL cholesterol is better, with no identified lower limit of harm, and highlights the growing importance of lipoprotein(a) screening in cardiovascular risk assessment. As lipid therapies continue to evolve, combining guideline-driven care, patient-centered decision-making, and equitable access remains essential to improving long-term cardiovascular outcomes. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Amber Johnson: Here

In this episode of MD Newsline, a distinguished panel of physicians, mental health leaders, former professional athletes, and performance coaches come together for a powerful discussion on men's mental health, vulnerability, and emotional wellbeing. The conversation explores how traditional definitions of masculinity impact mental health, performance, relationships, and help-seeking behaviors—and why redefining strength is critical for future generations. Panelists include Dr. Mike Banna, Dominique Easley, Jason Sousa, Dr. Nate Evans Jr., and Dr. Pete Thomas, each bringing unique perspectives from clinical medicine, elite athletics, mental performance coaching, and community leadership. Episode Highlights Why Men Struggle to Talk About Mental Health The panel examines how stigma, fear of judgment, and societal expectations of masculinity prevent men from opening up. They discuss how emotional suppression often begins early in life and carries into adulthood, affecting relationships, leadership, and self-identity. Redefining Strength and Masculinity Vulnerability is reframed as a core component of strength—not weakness. Panelists challenge outdated narratives that equate emotional expression with failure and emphasize that resilience begins with self-awareness and honesty. Mental Health, Athletic Performance, and Life After Sports Former NFL player Dominique Easley and performance coach Jason Sousa discuss how unaddressed mental health issues can impact athletic performance and create long-term challenges after retirement. They highlight the importance of identity beyond sport and the role of emotional intelligence in sustained success. Creating Safe Spaces for Men From barbershops and coffee shops to locker rooms and clinics, the panel shares real-world examples of environments where men feel safe enough to open up. Simple check-ins, active listening, and community-based conversations are emphasized as powerful entry points. The Role of Physical Health in Emotional Wellbeing Dr. Banna explains the close connection between physical and mental health, highlighting how sleep, exercise, diet, and outdoor activity directly influence mood, stress resilience, and emotional regulation. Turning Pain Into Purpose Dr. Nate Evans Jr. shares how unprocessed pain can limit growth, while intentional healing can transform lived experience into purpose and leadership. The discussion emphasizes that resilience is built—not inherited—and healing benefits both individuals and their communities. Hope for the Next Generation The panel expresses optimism about younger generations who are more open, emotionally aware, and willing to advocate for mental health support. Early education, open dialogue, and mentorship are seen as key drivers of lasting change. Key Takeaway True strength lies in self-awareness, vulnerability, and connection. By normalizing conversations around men's mental health and creating safe spaces for emotional expression, individuals and communities can foster healthier relationships, stronger leaders, and better outcomes across all areas of life.  Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Panelists: · Dr.  Mike Banna: Here ·       Dominique Easley: Here ·       Jason Sousa: Here ·       Dr. Nate Evans Jr:  Here

In this episode of MD Newsline, Dr. Rudolph J. Castellani, a neuropathologist and Director of the Division of Neuropathology at Northwestern University, offers a deep dive into the biology, diagnosis, and ongoing controversies surrounding Alzheimer's disease. He explores how Alzheimer's is defined clinically and pathologically, the evolving role of biomarkers in early detection, and why modifying biomarkers has not yet translated into meaningful clinical improvement for patients. Dr. Castellani also discusses the promise and limitations of artificial intelligence, personalized medicine, and lifestyle interventions in Alzheimer's research and care. Episode Highlights Defining Alzheimer's Disease Dr. Castellani explains how Alzheimer's disease can be defined clinically—through progressive memory and cognitive decline—or pathologically, based on hallmark brain lesions such as amyloid plaques and neurofibrillary tangles identified post-mortem. These structural changes remain central to diagnosis but do not fully explain disease progression. The Role of Amyloid and Biomarkers Amyloid beta, a key component of senile plaques, can now be detected through cerebrospinal fluid testing, blood-based biomarkers, and PET imaging. Dr. Castellani discusses how biomarkers help identify disease presence earlier but raises important questions about whether amyloid is a driver of disease or merely an associated marker. Early Detection: Promise and Ethical Concerns While biomarkers allow detection before symptoms appear, Dr. Castellani highlights the ethical dilemma of diagnosing asymptomatic individuals. He questions whether early identification without effective intervention may increase anxiety without improving outcomes. Therapies and Clinical Trial Limitations New anti-amyloid therapies, including FDA-approved agents, show only marginal cognitive benefit in highly selected trial populations. Dr. Castellani emphasizes caution when extrapolating these results to broader, more diverse patient groups and underscores the potential risks and toxicities associated with these treatments. Artificial Intelligence and Predictive Modelling AI and machine learning may enhance predictive modeling by integrating biomarkers, genetics, and cognitive data. However, Dr. Castellani notes that prediction alone is insufficient without therapies that meaningfully alter disease progression. Age of Onset and Risk Factors Alzheimer's disease can present as early as a patient's 30s in rare genetic cases or later in life in sporadic forms. Dr. Castellani reviews known risk factors, including APOE genotype, hypertension, diabetes, hearing loss, and traumatic brain injury, while stressing that many associations remain poorly understood. Personalized Medicine and Genetic Counseling Genetic testing—particularly for APOE and pathogenic mutations—plays a role in personalized risk assessment. Dr. Castellani emphasizes the importance of careful counseling, as not all individuals want or benefit from knowing their genetic risk. Supportive and Interdisciplinary Care With no curative treatments available, interdisciplinary care involving neurologists, neuropsychologists, and social workers is essential. Dr. Castellani highlights the importance of caregiver support, expectation management, and access to specialized centers. Lifestyle and Prevention Although lifestyle changes may not alter the underlying biology of Alzheimer's disease, healthy diet, exercise, and reducing inflammation and oxidative stress can improve quality of life and overall health. Key Takeaway Dr. Castellani underscores that while biomarkers and amyloid-focused therapies dominate current Alzheimer's research, they have not yet delivered meaningful clinical improvement. A broader research approach—beyond amyloid—combined with realistic expectations, ethical care, and strong support systems is essential for patients and families navigating Alzheimer's disease. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Rudolph J. Castellani: Here

In this episode of MD Newsline, a panel of men's health experts—Dr. Tracy Gapin, Dr. Joseph Acquaye, and Justin Birckbichler—come together to discuss a modern, proactive approach to men's health. The conversation explores the importance of prevention, hormone optimization, cardiovascular risk, and lifestyle-driven strategies to improve long-term health outcomes for men. The panel addresses common gaps in men's healthcare, including delayed screenings, lack of awareness around hormone health, and the cultural barriers that prevent men from seeking early medical intervention. Drawing from clinical experience and patient education, the speakers emphasize actionable steps clinicians can take to engage male patients more effectively. Episode Highlights The Importance of Preventive Care for Men The panel discusses why men are less likely to seek preventive care and how early screening for cardiovascular disease, metabolic health, and cancer can significantly improve outcomes. Routine checkups are positioned as essential, not optional. Hormone Health and Optimization Testosterone and hormone balance play a critical role in energy, mood, body composition, and sexual health. The speakers explain when hormone testing is appropriate and how evidence-based hormone optimization can support overall wellness when done responsibly. Cardiovascular and Metabolic Risk Awareness Heart disease remains a leading cause of death among men. The discussion highlights how lifestyle factors, inflammation, insulin resistance, and obesity intersect with cardiovascular risk—and how clinicians can intervene earlier. Lifestyle Medicine and Longevity Nutrition, sleep, stress management, and physical activity are framed as foundational pillars of men's health. The panel emphasizes sustainable lifestyle changes over quick fixes, with a focus on long-term vitality and performance. Improving Patient Engagement and Education The episode underscores the importance of communication strategies that resonate with male patients. Building trust, simplifying medical messaging, and reframing health as performance and longevity can drive better adherence. Key Takeaway Men's health requires a proactive, preventive, and personalized approach. By addressing hormone balance, cardiovascular risk, and lifestyle factors early, healthcare providers can help men live longer, healthier, and more engaged lives.   Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with the Panelists ·       Dr. Tracy Gapin: Here ·       Dr. Joseph Acquaye: Here ·       Justin Birckbichler: Here

In this episode of MD Newsline, we explore how technology, community, and innovative care models are reshaping the experience of living with type 1 diabetes. Endocrinologist Dr. Arti Thangudu joins patient advocates Amy Hsieh (TypeOneAmy) and Jillian Rihl (T1DChic) for an in-depth conversation on digital health, telemedicine, diabetes technology, and the importance of patient-centered care. Drawing from both clinical expertise and lived experience, the panel highlights how connected devices, online communities, and new care delivery models are improving outcomes while making diabetes care more human, accessible, and empowering. Episode Highlights The Evolution of Type 1 Diabetes Technology Dr. Thangudu discusses how diabetes care has transformed over the last decade, from fingerstick monitoring to continuous glucose monitoring (CGM) systems and hybrid closed-loop insulin pumps. These advancements have reduced treatment burden, improved glycemic control, and enhanced quality of life for many patients. Living With Type 1 Diabetes: Patient Perspectives Amy and Jillian share their personal journeys with type 1 diabetes, reflecting on how technology such as Dexcom CGMs and insulin pumps has simplified daily management. Jillian describes achieving dramatic improvements in A1C through integrated devices, while Amy highlights the freedom that real-time glucose data provides in everyday life. The Power of Online Community and Social Media The conversation explores how social media platforms have created vital support networks for people with type 1 diabetes. Amy and Jillian discuss building online communities that normalize the condition, share practical insights, and reduce stigma—especially for young adults navigating life with a chronic disease. Telemedicine and Virtual Diabetes Care Dr. Thangudu explains how telemedicine can match—and in some cases outperform—in-person care for diabetes management. With improved access to CGM and pump data, virtual visits allow for more frequent, meaningful interactions and better continuity of care, particularly for patients facing geographic or logistical barriers. Direct Care Endocrinology and Patient Advocacy Dr. Thangudu introduces the direct care model, emphasizing longer visits, improved access, and hands-on advocacy for patients. This approach allows clinicians to address urgent issues, coordinate hospital care, and prevent avoidable complications such as diabetic ketoacidosis (DKA). Patient-Centered Care and Shared Decision-Making Amy and Jillian highlight the importance of recognizing that type 1 diabetes is not "one size fits all." They advocate for individualized care plans, full transparency around technology options, and clinicians who actively listen to patients' lived experiences. Future Innovations in Diabetes Care The panel discusses what lies ahead, including advancements in automated insulin delivery, AI-driven diabetes technology, extended-wear CGMs, and ongoing research into potential cures. While technology continues to evolve, the group emphasizes that innovation in care delivery models is just as critical. Key Takeaway This episode underscores that the future of type 1 diabetes care lies at the intersection of technology, compassion, and collaboration. By integrating digital tools, patient voices, and innovative care models, clinicians and communities can work together to create more connected, effective, and human-centered diabetes care. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Arti Thangudu: Here

In this special panel episode of MD Newsline, recorded during Breast Cancer Awareness Month, a multidisciplinary group of experts and advocates explores the often-overlooked realities of breast cancer survivorship. Clinical psychologist and breast cancer survivor Dr. Christina Hibbert, breast and gynecologic medical oncologist Dr. Eleonora Teplinsky, and patient advocate and survivor Aisha Patterson share candid insights into the mental, emotional, social, and financial challenges that persist long after active treatment ends. Through both clinical perspectives and lived experiences, the panel highlights why survivorship is not an endpoint—but a lifelong phase requiring personalized, integrated support.  Episode Highlights The Mental and Emotional Impact of Breast Cancer The panel discusses how breast cancer diagnosis and treatment are inherently traumatic experiences. Anxiety, depression, and PTSD are common among survivors, particularly after treatment concludes, when support often fades. Dr. Hibbert emphasizes that survivorship can feel more difficult than active treatment and calls for mental health care to be integrated from diagnosis onward. Life After Treatment: Survivorship Is Forever Survivors share how ringing the bell does not mark a return to "normal." Lingering fatigue, chronic illness, fear of recurrence, and identity changes shape daily life. The panel reframes survivorship as an ongoing journey rather than a finish line. Financial Toxicity and Access to Care The discussion highlights how financial stress—from insurance gaps, treatment costs, lost income, and uncovered supportive therapies—directly impacts mental health and treatment adherence. Dr. Teplinsky explains how financial toxicity screenings and advocacy resources can help identify patients in need, while Aisha shares practical guidance on accessing grants and support programs. The Role of Community and Peer Support Social media and survivor communities play a vital role in helping patients feel seen and understood. Panelists discuss how peer networks often fill critical gaps left by traditional healthcare systems, especially for younger survivors navigating body image changes, early menopause, and long-term side effects. Caregiver and Family Support The episode underscores the emotional toll cancer takes on caregivers, partners, and children. The panel calls for better inclusion of caregivers in care planning, validation of caregiver burnout, and access to mental health resources for families affected by cancer. Redefining Thriving After Cancer Thriving looks different for every survivor. From redefining purpose and setting boundaries to honoring rest and self-care, the panel encourages patients and providers alike to embrace individualized definitions of healing and quality of life. Key Takeaway Breast cancer care must extend beyond physical treatment to address mental health, financial strain, relationships, and long-term survivorship needs. By normalizing emotional struggles, supporting caregivers, and connecting patients to meaningful resources, healthcare teams can help survivors feel less alone and more empowered throughout their journey. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with the Panelists ·        Aisha Patterson: Here ·        Dr. Christina Hibbert: https://drchristinahibbert.com/ ·        Dr. Eleonora Teplinsky: Here

In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical Therapy (GDMT) Dr. Youmans discusses the four pillars of GDMT for heart failure with reduced ejection fraction and how rapid initiation and optimization of therapy can significantly improve patient outcomes. He emphasises early sequencing, close follow-up, and collaboration with pharmacy teams to ensure patients receive maximal benefit. Device-Based Therapies in Advanced Heart Failure Innovations such as transcatheter mitral valve repair, pulmonary artery pressure monitoring, and advanced hemodynamic devices are reshaping heart failure care. Dr. Youmans explains how these technologies help reduce hospitalizations, improve symptoms, and support earlier intervention in high-risk patients. Health Disparities and Access to Care A major focus of the conversation centers on racial, socioeconomic, and geographic disparities in heart failure outcomes. Dr. Youmans highlights efforts to expand access through community-based clinics, telehealth, and outreach to rural and underserved populations. Sex-Based Differences and Cardiovascular Risk Across the Lifespan Dr. Youmans explores how pregnancy-related conditions such as preeclampsia increase long-term cardiovascular risk for women. He underscores the need for coordinated care between cardiology, OB-GYN, and primary care to support prevention and long-term monitoring. Multidisciplinary and Collaborative Care Models Heart failure management increasingly relies on collaboration across specialties, including nephrology, endocrinology, interventional cardiology, and surgery. Dr. Youmans discusses how integrated care models improve decision-making and patient outcomes, particularly in complex cases involving CKM (cardiovascular-kidney-metabolic) syndrome. Personalized Medicine and Biomarkers Biomarkers such as BNP play a growing role in risk stratification and treatment monitoring. Dr. Youmans explains how future approaches may tailor therapies based not only on biology, but also on patients' social environments and barriers to care. Emerging Therapies and the Future of Heart Failure Treatment From SGLT2 inhibitors and GLP-1 receptor agonists to new mineralocorticoid receptor antagonists, Dr. Youmans reviews promising pharmacologic advances for both HFrEF and HFpEF. He also shares perspectives on future innovations, including fully implantable LVADs, organ preservation technologies, and transplant expansion strategies. Key Takeaway Dr. Youmans emphasizes that the future of heart failure care lies at the intersection of innovation, equity, and collaboration. By combining advanced therapies with patient-centered communication and improved access, clinicians can meaningfully transform outcomes for diverse patient populations. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Quentin Youmans: Here

In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure, and the role of multidisciplinary care teams in supporting patients throughout their cancer journey. Episode Highlights Shifts in Breast and Prostate Cancer Detection Dr. Anupindi discusses increased awareness and earlier diagnosis of prostate cancer, particularly among younger men, driven by public education and PSA testing. She also reflects on breast cancer screening programs and the ongoing challenge of improving participation in minority and underserved communities. Cancer Awareness and Cultural Barriers Drawing from her experience working with South Asian communities, Dr. Anupindi addresses misconceptions around cancer, cultural taboos, and the importance of education in encouraging early screening and timely diagnosis. Younger Patients and Aggressive Disease Biology Younger breast cancer patients often present with more aggressive disease. Dr. Anupindi explains why oncologists tend to take a more proactive treatment approach in this population and highlights the role of hereditary cancer risk and hormonal factors. Key Advances from ESMO and Recent Trials Dr. Anupindi shares highlights from major oncology meetings, including discussions around reducing chemotherapy exposure in HER2-positive and hormone receptor–positive breast cancer. She also explains the clinical significance of trials focused on hormone resistance and targeted combination therapies. Fertility, Pregnancy, and Cancer Treatment The conversation explores data supporting temporary interruption of endocrine therapy for young women wishing to conceive. Dr. Anupindi emphasizes that cancer survivorship should include quality-of-life considerations, including fertility preservation and family planning. Access, Affordability, and Global Equity in Cancer Care Dr. Anupindi compares treatment access across healthcare systems, discussing regulatory pathways, cost considerations, and research into lower-dose therapies that may expand access without compromising outcomes. Technology, AI, and Precision Oncology From artificial intelligence in imaging and pathology to biomarker-driven therapies, Dr. Anupindi reflects on how technology is shaping more precise, efficient, and personalized cancer care. Multidisciplinary Care and Patient Support Team-based care is central to effective oncology treatment. Dr. Anupindi highlights the essential roles of nurses, radiographers, palliative care teams, and support workers in addressing patients' medical, psychological, and social needs. Quality of Life and Patient-Reported Outcomes As cancer treatments extend survival, Dr. Anupindi stresses the growing importance of quality-of-life measures in clinical trials and treatment decision-making, ensuring patients live better, not just longer. Key Takeaway Dr. Anupindi underscores that modern oncology is no longer focused solely on survival outcomes. Early detection, culturally sensitive education, targeted therapies, and quality-of-life considerations are essential to delivering truly patient-centered cancer care. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Aruna Anupindi:  Here

In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also addressing ethical considerations, data fairness, and the future of AI-driven decision-making in medicine. Episode Highlights AI in Clinical Trial Design and Drug Development Dr. Prelaj explains how AI tools are dramatically improving success rates in early-phase clinical trials. Technologies such as AlphaFold and predictive modeling are helping researchers identify promising drug targets, reduce trial failures, and optimize trial design before patients are enrolled. Predicting Trial Success and Reducing Failure AI-powered platforms can analyze historical clinical trial data to forecast the likelihood of success in Phase I, II, and III studies. Dr. Prelaj discusses how these insights benefit pharmaceutical companies, investigators, and ultimately patients by reducing exposure to ineffective treatments. Virtual Trials and Real-World Data Integration The conversation explores how virtual and pragmatic trial models leverage real-world data to simulate outcomes, relax restrictive inclusion criteria, and make trials more accessible to diverse patient populations—without compromising scientific rigor. Clinical Trial Matching and Physician Efficiency Dr. Prelaj highlights AI-driven clinical trial matching tools that can reduce physician workload by nearly 50%, helping clinicians quickly identify the most appropriate trials for individual patients while prioritizing those with the greatest potential benefit. Patient Advocacy and AI-Powered Access to Trials AI is empowering patients to actively participate in their care. Dr. Prelaj discusses patient-facing tools that allow individuals to identify relevant trials, initiate informed conversations with physicians, and advocate for access to cutting-edge treatments. Data Democratization, Bias, and Fairness The episode addresses critical challenges surrounding data governance, paywalled research, and underrepresentation in clinical trials. Dr. Prelaj explains how synthetic data and fairness auditing can help reduce disparities across race, ethnicity, and rare disease populations. The Future of AI in Oncology: Agents and Digital Twins Looking ahead, Dr. Prelaj shares her excitement about AI agents and digital twin models—dynamic systems that mirror real patients over time to support clinical decision-making, personalize treatment strategies, and enhance precision oncology. Key Takeaway Dr. Prelaj emphasizes that artificial intelligence is not replacing clinicians—but augmenting their expertise. By combining AI-driven insights with human judgment, oncology is entering a new era of smarter trials, more equitable care, and data-informed decision-making that has the potential to improve outcomes for patients worldwide.  Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Arsela Prelaj:  Here

In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System's Role in Triple-Negative Breast Cancer Dr. Loi explains why the immune system is critical in triple-negative breast cancer, a subtype known to respond well to immunotherapy. Her research focuses on immune cell infiltration, particularly T cells, and how immune surveillance affects tumor growth and patient outcomes. How Pregnancy and Breastfeeding Enhance T Cell Immunity The study reveals that women who have experienced pregnancy and breastfeeding have significantly higher T cell levels in normal, cancer-unaffected breast tissue. Dr. Loi walks through both human tissue analysis and mouse model data demonstrating that this immune enrichment plays a protective role against tumor development. Evidence from Preclinical and Clinical Models Dr. Loi describes experiments showing that tumors grow more slowly in mice that have undergone pregnancy, lactation, and involution. She also explains how T cell depletion removes this protective effect, confirming that immunity—rather than hormones alone—drives this benefit. Implications for High-Risk and Diverse Populations The protective immune effect was observed regardless of BRCA1 or BRCA2 mutation status. Dr. Loi also discusses how these findings may help explain differences in triple-negative breast cancer risk across populations and highlight the importance of breastfeeding support at a public health level. Toward Preventative Immunotherapy and Vaccines This research introduces a paradigm shift—from treating cancer to preventing it. Dr. Loi explores the potential for vaccines or immune-based therapies that mimic pregnancy-related immune reprogramming and emphasizes the importance of collecting reproductive history in oncology care and clinical trials. Future Directions: Screening, Technology, and Policy Dr. Loi discusses how reproductive history may influence response to immunotherapy, inform personalized screening strategies, and shape future research using AI, T cell receptor profiling, and blood-based early detection tests. She also underscores the societal importance of supporting breastfeeding through policy and workplace initiatives. Key Takeaway Dr. Loi highlights that pregnancy and breastfeeding create long-lasting, systemic immune changes that may protect against triple-negative breast cancer. Understanding how reproductive history reshapes immune surveillance opens new avenues for prevention, personalized treatment, and population-level strategies to reduce the global burden of breast cancer. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Sherene Loi:  Here

In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the modern classification of spondyloarthritis, distinguishing axial disease—which primarily affects the spine and sacroiliac joints—from peripheral spondyloarthritis and psoriatic arthritis. He discusses why the shift away from the term ankylosing spondylitis allows for earlier diagnosis before irreversible spinal fusion occurs. Recognizing Red Flags Across Specialties Inflammatory back pain remains the most important clinical clue, particularly pain that worsens at rest, improves with exercise, and is associated with prolonged morning stiffness. Dr. Wright also highlights extra-musculoskeletal signs—such as uveitis, psoriasis, and inflammatory bowel disease—that should prompt early referral to rheumatology. Classification Criteria vs. Clinical Judgment While ASAS classification criteria are useful for research, Dr. Wright emphasizes that real-world diagnosis relies on clinical expertise. Patients may not meet strict criteria early in the disease course, yet still warrant diagnosis and treatment based on symptoms, exam findings, labs, and imaging. MRI Use and Common Diagnostic Pitfalls MRI of the sacroiliac joints plays a central role in early detection, but Dr. Wright cautions against overreliance on imaging alone. Bone marrow edema can be seen in athletes, postpartum patients, or with aging, underscoring the importance of correlating MRI findings with clinical context. Biomarkers and Emerging Research HLA-B27, ESR, and CRP remain useful tools, though many patients have normal inflammatory markers. Dr. Wright discusses emerging biomarkers, including antibodies such as anti-CD74, and the need for more reliable tools to support earlier diagnosis. Treatment Algorithms and Medication Selection NSAIDs remain first-line therapy and may slow radiographic progression. For patients with inadequate response, Dr. Wright outlines escalation to biologics, including TNF inhibitors, IL-17 inhibitors, and JAK inhibitors—while tailoring choices based on comorbidities such as uveitis or inflammatory bowel disease. Treat-to-Target and Monitoring Early disease requires more frequent follow-up to assess response and adjust therapy. Dr. Wright explains realistic timelines for evaluating NSAIDs and biologics while balancing treat-to-target goals with clinic capacity. The Role of Exercise and Non-Pharmacologic Care Physical therapy, structured exercise, and low-impact activities such as swimming and cycling are foundational to care. Dr. Wright emphasizes the mental and physical benefits of movement, posture training, and holistic therapies alongside medication. Managing Comorbidities and Special Populations The discussion covers cardiovascular risk screening, adherence challenges in younger patients, biologic tapering in remission, pregnancy considerations, and care for older adults with established structural damage. Shared decision-making remains central across all scenarios. Key Takeaway Dr. Wright underscores that axial spondyloarthritis requires early recognition, thoughtful interpretation of imaging, and individualized treatment strategies. Combining pharmacologic therapy with exercise, multidisciplinary care, and patient education is essential to improving quality of life and preventing long-term disability. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Joel Wright: Here

In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the leading cause of MS—interacts with genetic susceptibility and immune regulation. She also explores the future of AI in epidemiological research, the challenges of defining "deficiency" across diverse populations, and how personalized medicine may change MS prevention and treatment. Episode Highlights Understanding the Vitamin D–MS Connection Dr. Cortese explains her landmark study assessing vitamin D levels in over 1,400 MS cases and double the number of controls from a U.S. military cohort. The findings show that higher vitamin D levels are associated with a 60% lower risk of MS, even among individuals who already meet current "sufficient" vitamin D thresholds. Epstein-Barr Virus as a Causal Factor She details how EBV infection precedes nearly all MS diagnoses, increasing risk 32-fold in those infected compared to those who remain uninfected. The 2022 Science paper by her team was pivotal in confirming EBV as the primary cause of MS. Racial and Genetic Differences in Vitamin D Physiology Dr. Cortese emphasizes that Black populations may metabolize vitamin D differently, which could explain why prior studies found weaker associations between vitamin D levels and MS risk. Her ongoing work includes genotyping vitamin D transport proteins and analyzing ethnic variations in MS susceptibility. Public Health Implications and Future Research Given vitamin D's safety, affordability, and widespread deficiency, Dr. Cortese advocates for revised supplementation guidelines tailored to disease prevention. She also highlights future research directions involving AI-driven data analysis, omics studies, and therapeutic vaccines or antivirals targeting EBV. A Look Toward MS Prevention and Treatment Dr. Cortese envisions a future where antiviral therapies against EBV could transform MS management—potentially leading to disease-modifying or curative interventions. Meanwhile, maintaining sufficient vitamin D remains a key, accessible step for reducing risk. Key Takeaway Dr. Cortese's research bridges decades of inquiry into how vitamin D and EBV intersect to influence MS risk. Her findings reinforce the importance of immune health, genetic understanding, and early prevention, paving the way for more personalized and equitable approaches to neurological care. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Marianna Cortese: Here

In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on experiencing painful boils as early as adolescence, often dismissed as razor bumps, cysts, or irritation. Despite recurring symptoms, she did not receive an HS diagnosis until 2019—highlighting a common challenge many HS patients face. Impact of Hormones and Life Changes Symptoms became more frequent and severe in her early 20s, particularly after pregnancy. Over time, Tameka began noticing patterns related to her menstrual cycle, helping her better understand flare triggers. The Emotional and Physical Burden of HS Living with chronic pain, drainage, and scarring significantly affected Tameka's quality of life and confidence. She shares how unmanaged HS can quietly take over daily living when symptoms become constant. Finding the Right Specialist Tameka emphasizes the turning point in her care after seeking a dermatologist who specializes in HS. Under the care of Dr. Onajin, she experienced a more aggressive, responsive treatment approach that prioritized real pain reduction and patient feedback. Personalized Treatment and Pain Measurement Rather than a one-size-fits-all approach, treatment success was measured by meaningful pain reduction percentages. This patient-centered strategy allowed Tameka and her care team to adjust therapies quickly when something wasn't working. Procedures, Medications, and Combination Care Tameka discusses the role of biologics, steroid injections, surgical procedures, and scar tissue removal as part of a comprehensive treatment plan—emphasizing that improvement was gradual, not overnight. Nutrition and Lifestyle as Key Triggers Diet emerged as one of the most impactful factors in managing HS. Tameka shares how eliminating refined sugar, dairy, and soda helped reduce flares, improve energy levels, and support overall well-being. Advocacy, Education, and Listening to Your Body A strong advocate for patient education, Tameka encourages others to research their condition, speak up when treatments fail, and seek second or third opinions. She underscores that patients know their bodies best—and deserve to be heard. Advice for Patients and Providers Tameka offers powerful guidance for those living with HS and for healthcare providers: listen, communicate clearly, and treat patients as partners in care. Key Takeaway Tameka Carter's story highlights the importance of early recognition, specialist care, and patient advocacy in managing hidradenitis suppurativa. Meaningful progress happens when patients are heard, treatments are personalized, and care teams act with urgency and compassion. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of relapse. By analyzing blood-based metabolic signatures, her team is uncovering how these foods interact with biological pathways tied to chronic inflammation and neurodegeneration. Dr. Dalla Costa also discusses the Nova classification of processed foods, the role of ceramides and other metabolites in cellular health, and how regional dietary patterns affect disease outcomes. She emphasizes the importance of adopting a Mediterranean-style diet and reducing ultra-processed food intake as a modifiable lifestyle factor that can complement established MS therapies. Episode Highlights Exploring Environmental Risk Factors for MS Dr. Dalla Costa explains how her team investigates multiple environmental contributors to MS, including Epstein–Barr virus exposure, vitamin D levels, and now, ultra-processed food intake. Ultra-Processed Foods and Disease Activity Her findings show that MS patients with higher levels of ultra-processed food metabolites in their blood experience 30% more relapses and worse MRI lesion progression over five years. Metabolic Signatures and Biomarkers Dr. Dalla Costa outlines how measuring circulating metabolites in blood and urine offers an innovative way to assess dietary exposure objectively, bypassing unreliable food questionnaires. Dietary Classification and Health Impact The Nova system distinguishes between unprocessed, minimally processed, processed, and ultra-processed foods. Additives, preservatives, and colorants—while convenient—are linked to inflammation and metabolic stress. Towards Personalized Nutrition in MS Emerging evidence suggests that dietary modification could become a complementary approach in MS management. Dr. Dalla Costa envisions a future where AI and machine learning will personalize nutritional recommendations for patients. Future Directions in Research Her team plans to explore how ultra-processed foods affect the gut barrier, contribute to chronic inflammation, and potentially inform dietary policy and patient education globally. Key Takeaway Dr. Dalla Costa underscores that reducing ultra-processed food intake may serve as a simple yet powerful tool to support neurological health in MS patients. By combining validated therapies with mindful dietary choices, clinicians and patients can work together to mitigate inflammation and improve long-term outcomes.  Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Gloria Dalla Costa:  Here

In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and neurodegenerative processes in MS. From identifying axonal damage to detecting astrocyte activation and microglial involvement, these biomarkers are transforming how clinicians assess disease activity and progression risk. Dr. Abdelhak also discusses the potential of machine learning and AI-based models in interpreting complex, multi-center datasets — paving the way for personalized treatment strategies. He emphasizes the importance of cross-specialty collaboration, incorporating radiology, immunology, and physical therapy, to deliver holistic MS care that addresses both neurological and everyday challenges faced by patients. Episode Highlights Advancements in MS Biomarkers Dr. Abdelhak reviews emerging biomarkers — including GFAP and chitinases — and explains their cellular origins, from astrocytes to microglia, offering a multidimensional view of disease mechanisms. Clinical Value of GFAP and NFL He explains how GFAP reflects astrocyte activation and correlates with disease progression, while NFL indicates axonal damage. Combining both markers enables a more precise prediction of MS activity and long-term disability outcomes. Machine Learning and Data Integration AI is reshaping MS research by harmonizing large, noisy datasets and uncovering biologically meaningful clusters of patients. This integration of fluid, imaging, and genetic data supports early identification of disease subtypes and better treatment matching. Personalized and Holistic MS Management Dr. Abdelhak underscores the future of individualized biomarker trajectories, which could guide treatment adjustments and predict therapy response. He also highlights the need for patient advocacy, encouraging individuals to voice concerns about cognitive symptoms, fatigue, and depression often overlooked in clinical settings. The Path Ahead for MS Research He anticipates major breakthroughs in the next five years, especially in identifying new biomarker panels and understanding under-researched pathways involving astrocytes and microglia. Collaboration across specialties and clearer communication with patients will be crucial to translating these scientific insights into daily clinical care. Key Takeaway Dr. Ahmed Abdelhak emphasizes that fluid biomarkers are redefining MS care — enabling earlier, more accurate detection of disease progression and treatment response. The integration of AI tools, multi-omics data, and cross-specialty collaboration is driving a new era of precision medicine in neurology, offering patients more informed and individualized care pathways. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Ahmed Abdelhak: Here

In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in remyelination research are shaping the future of MS treatment. Episode Highlights Epidemiology and Patient Demographics Dr. Kale explains that autoimmune neurological disorders such as MS and optic neuritis predominantly affect young women in their childbearing years. She attributes this trend to the interplay of hormonal, genetic, and environmental factors, including vitamin D deficiency, Epstein–Barr virus exposure, and obesity. Pathophysiology of MS and Optic Neuritis She provides a detailed overview of how immune system activation, particularly involving T cells, B cells, and cytokines, leads to demyelination and subsequent neurodegeneration. While early disease stages may allow remyelination, progressive degeneration contributes to long-term disability. Diagnosis and Differential Considerations Dr. Kale emphasizes that early and accurate diagnosis is critical to preventing irreversible damage. Conditions such as neuromyelitis optica (NMO) and MOG antibody disease (MOGAD) can mimic MS, underscoring the need for MRI imaging, CSF analysis, and antibody testing to guide correct classification and treatment. Clinical Presentation and Early Detection Optic neuritis often presents with eye pain, color desaturation, and central vision loss. Dr. Kale notes that orbital and cranial MRI scans with contrast are essential for confirming inflammation and ruling out other causes such as ischemic optic neuropathy or ophthalmologic conditions. Treatment Strategies and Advances Standard management involves high-dose intravenous corticosteroids to accelerate visual recovery and delay MS onset, as shown in the Optic Neuritis Treatment Trial (ONTT). For severe or atypical cases, Dr. Kale recommends plasmapheresis or IV immunoglobulin (IVIG) therapy. She stresses tailoring therapy to the individual patient, noting that treatment protocols for MS, NMO, and MOGAD differ significantly. Evolving Therapies and Global Access Dr. Kale reflects on the progress from early interferon-based therapies to modern monoclonal antibody treatments, highlighting how health policy and access continue to affect patient outcomes worldwide. Emerging Research and Biomarkers Advances in PET imaging and astrocyte-targeted ligands show promise for identifying chronic lesions and smoldering plaques, which could pave the way for future remyelination-focused treatments. Patient-Centered Care and Gender Considerations Beyond science, Dr. Kale underscores the emotional and social burden faced by women living with MS—balancing family responsibilities, work, and health. She advocates for stronger patient networks and social support systems to improve quality of life. Key Takeaway Dr. Kale emphasizes that timely diagnosis, personalized therapy, and advances in neuroimaging and immunology are transforming MS and optic neuritis care. She calls for continued collaboration between clinicians, researchers, and policymakers to ensure equitable access to modern treatments and better long-term outcomes for patients. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Nilüfer Kale: Here

In this episode of MD Newsline, Dr. Frank Weinberg, a thoracic oncologist at the University of Illinois Cancer Center, explores the groundbreaking integration of artificial intelligence (AI) into lung cancer screening. As the senior author and a key collaborator in the SIBL (Sybil) Consortium, Dr. Weinberg shares how this AI tool—originally developed by MIT's Regina Barzilay and validated at Mass General Hospital—is being expanded to assess its effectiveness in diverse and underserved populations. He discusses how SIBL uses low-dose CT scans to predict a patient's six-year risk of developing lung cancer, addressing a critical gap in current screening guidelines that often overlook individuals who don't meet standard age or smoking history criteria. Through collaboration with colleagues like Mary Pasquinelli, Dr. Weinberg highlights how the University of Illinois is advancing precision-based lung cancer screening that reflects real-world diversity. Episode Highlights AI for Early Lung Cancer Detection Dr. Weinberg explains how the SIBL tool analyzes CT scans to detect subtle patterns invisible to the human eye—allowing clinicians to predict lung cancer risk before tumors are visible. Unlike traditional screening models based solely on age and smoking history, SIBL offers a personalized, data-driven approach. Expanding Validation Across Diverse Populations The SIBL Consortium, which includes UIC, Baptist Memorial (Tennessee), and WellStar (Southeast U.S.), is working to validate the AI tool in heterogeneous populations. The goal is to ensure that racial and socioeconomic diversity is represented in lung cancer screening research. Integrating Biology with AI Insights Dr. Weinberg discusses his lab's efforts to combine biological data—such as cytokine levels, metabolites, and genetic profiles—with SIBL scores. This approach aims to deepen understanding of oxidative stress, inflammation, and genomic markers that influence lung cancer risk. From Screening to Prevention Moving beyond detection, Dr. Weinberg envisions a future of precision-guided lung cancer prevention, where AI-driven insights and biomarker data could identify high-risk patients and enable early interventions to reduce cancer incidence altogether. Bridging Health Disparities Because current screening criteria disproportionately exclude Black and underserved patients, validating SIBL in diverse cohorts can help correct systemic inequities. Dr. Weinberg emphasizes that technology like SIBL, when responsibly deployed, can reduce disparities and improve early detection outcomes. Challenges and Next Steps Dr. Weinberg also reflects on the technical, ethical, and logistical challenges of implementing AI tools in healthcare systems. From data privacy and interoperability to community trust and educational outreach, he stresses that responsible innovation requires collaboration between clinicians, data scientists, and patients alike. Key Takeaway Dr. Frank Weinberg underscores the transformative potential of AI-powered precision medicine to revolutionize lung cancer screening and reduce disparities in healthcare. By validating tools like SIBL across diverse populations and integrating biological, clinical, and social data, the medical community can move closer to achieving truly equitable early detection and prevention. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Frank Weinberg: Here

In this episode of MD Newsline, Dr. Dillon Bannis, an OB-GYN practitioner based in the South Side of Chicago, shares his insights on the evolving challenges and innovations in obstetric and gynecological care. Dr. Bannis explores how listening, collaboration, and technology are reshaping the patient experience—from prenatal care and delivery practices to addressing health disparities and integrating AI into medicine. With a strong emphasis on patient-centered communication, interdisciplinary collaboration, and technological integration, Dr. Bannis highlights how practitioners can balance innovation with compassion in women's healthcare. Episode Highlights Bridging the Gap Between Innovation and Implementation Dr. Bannis discusses the lag between medical innovation and real-world practice, citing examples such as updated cervical cancer screening guidelines. He stresses that while medicine continues to advance rapidly, implementation often lags behind, emphasizing the need for better education, awareness, and adaptability among clinicians. The Power of Listening in Patient Care According to Dr. Bannis, listening is one of the most underrated skills in medicine. By prioritizing patient voices, physicians can build stronger relationships and facilitate shared decision-making, leading to more trusting and effective care outcomes. Advances in Obstetric Technology Dr. Bannis highlights promising innovations aimed at reducing maternal morbidity and mortality, particularly through hemorrhage prediction and prevention technologies. These tools, he explains, are transforming labor and delivery outcomes across practices. Cultural Competence and Birth Planning Drawing from his experience working alongside certified nurse midwives, Dr. Bannis advocates for respecting patients' birth preferences, whether it's squatting, all-fours positions, or doula-assisted births. He believes honoring cultural diversity in birthing methods contributes to better physical and emotional outcomes. Collaborative Care for High-Risk Pregnancies In complex cases involving oncology or high-risk pregnancies, Dr. Bannis underscores the importance of seamless communication between community and academic hospitals. He explains that efficient information sharing and inter-institutional collaboration can prevent medical errors and ensure no patient "falls through the cracks." Socioeconomic Factors and Health Disparities Dr. Bannis addresses how socioeconomic status affects access to prenatal care, nutrition, and birth outcomes. He calls for systemic efforts to tackle the social determinants of health and to make preventive screening more accessible to underserved populations. Empowering Patients Through Technology He emphasizes the importance of giving patients ownership of their medical records and using digital tools for education and engagement. By involving families and support systems, technology can enhance adherence, understanding, and long-term health outcomes. AI and the Future of Medical Communication Dr. Bannis envisions AI as a bridge between medical jargon and patient comprehension—translating complex medical notes into accessible summaries and breaking down language and cultural barriers. He also discusses how AI can streamline research and accelerate innovation in women's health. From Doulas to Robotics: The Expanding Role of Innovation Dr. Bannis explores the complementary roles of doulas, midwives, and robotic-assisted surgeries in modern OB-GYN care. He highlights that the field is moving from invasive solutions like hysterectomy toward minimally invasive and patient-preserving approaches, including uterine fibroid embolization. Key Takeaway Dr. Dillon Bannis emphasizes that true progress in women's health lies at the intersection of empathy and innovation. By actively listening to patients, embracing technological advancement, and addressing health disparities, practitioners can create a more equitable, efficient, and compassionate healthcare system for all. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Dillon Bannis: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Wanda Averhart, a general pediatrician and obesity medicine specialist, explores the complex causes and lifelong impacts of childhood obesity, emphasizing how early feeding practices, maternal health, and social disparities shape children's long-term outcomes. Dr. Averhart provides a comprehensive look at how environmental, cultural, and biological factors contribute to rising obesity rates among children—especially in underrepresented communities. She discusses the importance of infant feeding patterns, maternal diabetes and stress, and access to nutrition in determining early weight trajectories. Her insights reveal that addressing obesity begins before birth, and that family education and community-based interventions are key to prevention. Episode Highlights: Understanding Childhood and Infant Obesity Dr. Averhart explains that while "infant obesity" isn't technically defined, early feeding habits play a crucial role in a child's risk for obesity. Factors such as maternal health during pregnancy, feeding type, and cultural feeding practices all influence growth and metabolic outcomes. The Role of Feeding Practices and Culture From breastfeeding and formula feeding to early solid food introduction, Dr. Averhart emphasizes how cultural norms and parental beliefs shape feeding behavior. Introducing solid foods too early—especially high-sugar or fried foods—can increase obesity risk later in life. Environmental and Socioeconomic Factors She discusses how food deserts, limited access to fresh produce, and economic barriers make it difficult for many families to follow nutritional guidelines. Dr. Averhart highlights programs like WIC and SNAP that can provide critical nutritional support. Maternal Health and Stress Dr. Averhart outlines how maternal obesity, diabetes, and stress can biologically influence a child's future weight and metabolism through hormonal pathways like cortisol. She also connects maternal mental health to early childhood nutrition and caregiving quality. The Rise of Pediatric Comorbidities She notes an alarming increase in fatty liver disease, hypertension, and prediabetes among children—conditions once rare in pediatrics. These comorbidities disproportionately affect Black and Hispanic children and those from low-income households. Emerging Treatments and Future Research Dr. Averhart discusses the growing field of pediatric obesity treatment, including the use of GLP-1 receptor agonists (like semaglutide) in adolescents. However, she stresses that compassion, education, and prevention remain the most effective strategies. Key Takeaway Dr. Averhart calls on healthcare providers to approach obesity with empathy and understanding, recognizing it as a chronic, relapsing condition. She encourages clinicians to combine medical management, cultural awareness, and community engagement to support children and families most at risk. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Wanda Averhart: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Shaina A. Rozell, a hematologist-oncologist at Affiliate Oncology in Chicago, Illinois, explores the rapidly advancing field of multiple myeloma treatment. She discusses how quadruplet therapies, MRD monitoring, and novel immunotherapies like bispecific antibodies and CAR-T are transforming outcomes for patients. Dr. Rozell also examines disparities in access to care, the growing role of community practices in clinical trials, and the balance between extending survival and preserving quality of life. Episode Highlights 1. The Rise of Quadruplet Therapy Dr. Rozell explains how treatment has evolved from triplet to quadruplet regimens, incorporating agents such as daratumumab and isatuximab. These combinations have led to higher sustained MRD negativity and longer progression-free survival, offering some patients an alternative to stem cell transplantation. 2. Redefining the Role of Stem Cell Transplant While autologous transplants remain a mainstay, Dr. Rozell notes that emerging immunotherapies may one day reduce their necessity. She compares the shift in multiple myeloma to the eventual phasing out of stem cell transplants in breast cancer. 3. CAR-T and Bispecific Antibodies Access and feasibility play major roles in therapy selection. Dr. Rozell contrasts CAR-T—limited to tertiary centers—with bispecifics, which can now be administered in some community practices. Collaboration between local clinics and academic centers remains crucial for expanding access. 4. Supportive Care and Toxicity Management Advances in bone protection, infection prevention, and supportive care bundles are improving patient quality of life. However, Dr. Rozell underscores the ongoing challenge of managing long-term toxicities like neuropathy and heart failure. 5. Genetic and Cytogenetic Factors Cytogenetic abnormalities such as 17p deletions continue to shape prognosis and treatment choice. Dr. Rozell highlights the need for consistent genetic testing and patient education to ensure optimal therapeutic decisions. 6. Clinical Trial Diversity and Representation Dr. Rozell advocates for greater minority participation in clinical research, emphasizing the importance of trust, communication, and representation among both patients and providers to ensure equitable advancement of care. 7. The Future of Myeloma Research Looking ahead, Dr. Rozell anticipates MRD will become a central endpoint in clinical trials. She envisions a future with more home-based treatments, enhanced telemedicine integration, and continued innovation in supportive care and survivorship strategies. Key Takeaway Dr. Shaina Rozell underscores the transformation of multiple myeloma treatment through quadruplet therapies and MRD-driven care. By combining innovation, equity, and collaboration between community and academic centers, the field is moving closer to more accessible, effective, and personalized care for all patients. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Shaina A. Rozell: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Tonia L. Farmer, a board-certified otolaryngologist and head & neck surgeon, discusses the gaps in ENT care, the growing impact of HPV-related cancers, and the importance of education and early detection in improving outcomes—particularly for underserved communities. Drawing from years of practice, Dr. Farmer explores how social, behavioral, and environmental factors shape ENT health and shares insights on emerging research and technologies revolutionizing the field. Episode Highlights Addressing Racial and Socioeconomic Disparities Dr. Farmer highlights the persistent disparities in ENT care, especially among Black patients, who often present with more advanced head and neck cancers. She attributes these gaps not only to mistrust in healthcare systems but also to delayed care-seeking behaviors and limited access to specialists. By increasing community education and early screening, she emphasizes the potential to close these gaps. Lifestyle Trends and HPV-Related Throat Cancers Dr. Farmer discusses the rise of HPV-related oropharyngeal cancers, noting how sexual behavior trends—including unprotected oral sex and multiple partners—have contributed to a surge in HPV-16–linked head and neck cancers. She stresses that while most HPV infections clear naturally, persistent infections can remain dormant for decades, leading to cancer later in life. Her message is clear: education and vaccination are key preventive tools. Recognizing Early Symptoms and Common Misdiagnoses Many patients miss early warning signs of throat cancer—such as persistent sore throat, voice changes, unilateral ear pain, or lumps in the neck. Dr. Farmer explains that these symptoms are frequently mistaken for minor infections or TMJ disorders. She urges primary care providers to be aware of these red flags to ensure timely ENT referrals and faster diagnosis. Emerging Research and Technological Advances Dr. Farmer shares her excitement about ongoing research in oral HPV testing and tinnitus management—including potential implant technologies that could reduce chronic ringing in the ears. She also discusses how robotic-assisted surgery is transforming head and neck procedures and how AI may soon reshape diagnostics and patient engagement. Environmental and Social Impacts on ENT Health Environmental issues, such as air pollution from wildfires, chemical spills, and urban exposure, are increasingly linked to respiratory and sinus disorders. Dr. Farmer notes how such factors exacerbate conditions like sinusitis and chronic throat irritation, especially in vulnerable communities. The Power of Education and Social Media Beyond her clinical work, Dr. Farmer uses social media as an educational platform to spread accurate ENT health information. She believes digital outreach plays a crucial role in combating misinformation, empowering patients, and improving public understanding of ENT health. Key Takeaway Dr. Tonia L. Farmer emphasizes that early education, lifestyle awareness, and preventive care are vital in reducing ENT health disparities. Through research, technology, and public engagement, clinicians can help patients recognize symptoms earlier, make informed health choices, and improve outcomes across diverse populations. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Tonia L. Farmer: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Christopher Kaisa, Assistant Professor of Medicine in the Section of Gastroenterology, Hepatology, and Nutrition at the University of Chicago Medicine, provides an in-depth discussion on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the evolving strategies for its management. He explains the latest non-invasive diagnostic tools, pharmacologic advancements, and the importance of multidisciplinary care in improving outcomes for patients with metabolic liver disease. Episode Highlights: Patient Populations and Risk Factors Dr. Kaisa describes how obesity, type 2 diabetes, and hypertension significantly increase the risk of developing MASH. He notes that up to 75% of patients with obesity and diabetes may have some form of fatty liver disease—underscoring the urgent need for early detection and intervention. Gaps in Primary Care and Early Detection He discusses existing gaps in primary care screening, emphasizing the importance of education and access to specialized metabolic liver clinics. Early identification of at-risk patients using tools like FibroScan and non-invasive fibrosis scores can dramatically change patient trajectories. Risk Stratification and Fibrosis Assessment Dr. Kaisa details how fibrosis staging correlates with both cardiovascular and liver-related mortality. He explains the use of non-invasive tests (NITs)—including FibroScan and fibrosis scores—to monitor disease progression and therapy response over time. Therapies and Monitoring The episode highlights new treatments, such as resmetirom and GLP-1 receptor agonists (e.g., semaglutide), which have shown fibrotic and inflammatory benefits in clinical trials. Dr. Kaisa explains how these agents are monitored, when to adjust dosages, and how to manage common gastrointestinal side effects. Multidisciplinary Collaboration Dr. Kaisa emphasizes the value of a multidisciplinary team, including hepatologists, endocrinologists, dietitians, and pharmacists, to manage the complex comorbidities associated with MASH. This integrated approach enables personalized and effective care for each patient. The Role of Genetics and Personalized Medicine He also discusses the PNPLA3 genetic variant, a known risk factor among certain ethnic groups, particularly those of Hispanic descent. Recognizing genetic predispositions helps clinicians counsel patients on modifiable risk factors such as diet, exercise, and metabolic control. Clinical Trials and Access to New Treatments Dr. Kaisa explains how clinical trials serve as vital access points for emerging therapies, especially for patients who may not tolerate or qualify for current treatments. He stresses the need to broaden patient participation in research to ensure equitable advancement in the field. Key Takeaway Dr. Kaisa underscores the critical importance of early detection, comprehensive metabolic management, and multidisciplinary collaboration in treating MASH. With the recent FDA approval of semaglutide for MASH, and ongoing advancements in personalized medicine, clinicians have powerful new tools to change the trajectory of this increasingly prevalent disease. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Christopher Kaisa: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Rachael Sood, a diabetes nurse practitioner and certified diabetes care and education specialist from New Orleans, Louisiana, shares her insights from the 85th American Diabetes Association Scientific Sessions. As the founder of The Diabetes Collective, Dr. Sood discusses the evolution of diabetology—a specialized field focused solely on the identification, treatment, and management of diabetes across all patient populations. Dr. Sood explores how personalized diagnostics, innovative technology, and education-driven care models are reshaping outcomes for patients with type 1, type 2, and prediabetes. She highlights the importance of accurate diagnosis, the role of genetic predisposition, and why clinicians must move beyond relying solely on hemoglobin A1C levels to ensure proper disease identification and management. Episode Highlights Transforming the Diagnosis and Management of Diabetes Dr. Sood explains the principles of diabetology and how it differs from traditional endocrinology. She emphasizes comprehensive assessment, including antibody screening, glucose monitoring, and the integration of genomic insights to accurately distinguish between type 1 and type 2 diabetes. Technology as a Game-Changer in Diabetes Care Dr. Sood shares how continuous glucose monitors (CGMs) and insulin pumps have revolutionized real-time patient engagement. These smart biosensors empower patients to understand how lifestyle, stress, and nutrition directly affect glucose levels, fostering self-awareness and adherence to treatment plans. Overcoming Clinical Inertia and Patient Barriers She highlights the need to address clinical inertia, encouraging clinicians to adapt treatment plans as patients' needs evolve. Dr. Sood underscores the importance of patient education, empathy, and collaboration with family and community networks to improve adherence and reduce care fatigue. Breakthroughs in Treatment and Research Reporting from the ADA conference, Dr. Sood discusses the promising results of Vertex Pharmaceuticals' islet cell therapy, which shows evidence of restoring natural insulin production in type 1 diabetes. She also explains the role of TZLD (teplizumab) in delaying the onset of type 1 diabetes, potentially changing the disease trajectory for high-risk patients. Next-Generation Therapies and GLP-1 Innovation Dr. Sood breaks down the expanding role of GLP-1 receptor agonists—from glucose regulation to benefits in cardiovascular health, weight management, and chronic kidney disease. She reveals data on the new CagreSema combination therapy, which combines semaglutide with an amylin analog, showing over 20% weight reduction and improved metabolic outcomes. Insurance and Access Challenges Dr. Sood addresses the ongoing struggle of insurance coverage, prior authorizations, and high costs for new medications, offering practical advice for clinicians and patients to navigate access through manufacturer programs and cash-based options. Key Takeaway Dr. Sood emphasizes that diabetes care is entering a transformative era—one defined by early detection, patient empowerment, and precision medicine. With new therapies, technologies, and care models emerging rapidly, collaboration among clinicians, patients, and innovators will be essential to achieving long-term success in diabetes prevention and management. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Rachael Sood: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Martin Kaiser, Consultant Hematologist at the Royal Marsden Hospital and Professor of Hematology at the Institute of Cancer Research, London, discusses groundbreaking advances in the diagnosis and management of high-risk multiple myeloma. Drawing insights from the OptiMUM trial and related studies, Dr. Kaiser explores how genetic profiling, long-term treatment intensity, and personalized approaches are transforming patient outcomes. He also examines the challenges of treatment accessibility, the promise of T-cell–based therapies, and the evolving role of AI and MRI technology in hematology. Episode Highlights Understanding High-Risk Myeloma Dr. Kaiser explains that multiple myeloma varies greatly between patients, with high-risk myeloma representing the most aggressive form. Recent progress in genetic diagnostics now enables clinicians to identify these patients more accurately using chromosomal translocations, deletions, and point mutations such as TP53. New Guidelines and Diagnostic Tools He highlights a newly published international guideline that promotes the use of advanced genetic and molecular tools to define high-risk myeloma. This progress allows for more precise risk stratification and individualized care planning. The OptiMUM Trial: Redefining Treatment Duration Dr. Kaiser shares results from the OptiMUM trial, which demonstrated that maintaining treatment intensity beyond the initial six months leads to dramatically improved outcomes—nearly tripling progression-free survival and significantly extending overall survival. He emphasizes that balancing side effects with efficacy is key, and patient feedback plays a central role in long-term management. Inclusivity in Clinical Research The OptiMUM study included 39 hospitals across the UK, including community and rural centers, ensuring that data represented diverse and underserved populations. This broad inclusion provides strong evidence for the real-world effectiveness of intensive therapy. Emerging Therapies and the Future of Care Dr. Kaiser discusses T-cell–based treatments, including CAR-T cells and bispecific antibodies, which are showing remarkable efficacy in relapsed or refractory myeloma. He anticipates their movement into earlier lines of therapy, potentially reshaping high-risk myeloma management in the coming years. Balancing Quality of Life and Long-Term Treatment Sustained therapy requires careful patient–physician collaboration. Dr. Kaiser stresses the importance of listening to patients, managing side effects proactively, and individualizing care to maintain adherence without compromising quality of life. Monitoring and Diagnostics Innovations He describes advances in whole-body MRI and minimal residual disease (MRD) testing, which provide earlier and more sensitive detection of relapse. Combined with regular blood monitoring, these innovations support proactive, precision-guided care. Looking Ahead: AI and Genomic Insights Dr. Kaiser envisions AI-driven imaging and data analysis as the next frontier in myeloma diagnostics. By combining genetic, epigenetic, and imaging data, AI tools could soon enhance diagnostic speed, accuracy, and personalization in clinical practice. Key Takeaway Dr. Martin Kaiser emphasizes that high-risk myeloma care is entering a new era—defined by genomic precision, long-term treatment optimization, and advanced diagnostics. By sustaining therapy intensity and improving diagnostic access, clinicians can achieve longer remissions and better survival outcomes. Collaboration among healthcare systems, researchers, and patients remains vital to ensure equitable access to these life-extending innovations. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Martin Kaiser: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Mark R. Litzow, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, discusses the groundbreaking findings from the ECOG-ACRIN E1910 trial and the evolving role of immunotherapy in acute lymphoblastic leukemia (ALL). He explores how real-world evidence complements clinical trials, the challenges of standardizing measurable residual disease (MRD) testing, and the future of personalized treatment strategies in hematologic malignancies. Dr. Litzow shares deep insights into how immunotherapy has transformed survival outcomes, how clinicians can balance efficacy and neuropsychiatric side effects, and why cross-disciplinary collaboration is key to advancing oncology care. Episode Highlights Real-World Evidence and Clinical Practice Dr. Litzow explains the growing importance of real-world data in validating and refining clinical trial outcomes. While clinical trials have strict eligibility criteria, real-world settings introduce more patient diversity, offering valuable insights into treatment efficacy and tolerability across broader populations. The ECOG-ACRIN E1910 Trial and Immunotherapy Advances Dr. Litzow details the E1910 trial, which compared standard chemotherapy with and without blinatumomab, an immunotherapy agent targeting CD19 and CD3. The study demonstrated a significant survival benefit—85% versus 68%— for patients receiving blinatumomab, establishing it as a new standard of care for MRD-negative ALL patients. Integrating MRD and Genomic Profiling in Decision-Making He highlights how MRD testing and molecular risk profiling are shaping treatment pathways, enabling clinicians to better identify patients who can potentially avoid bone marrow transplantation through effective immunotherapy. Adapting Pediatric Regimens for Adult Patients Dr. Litzow discusses the use of pediatric-inspired chemotherapy regimens in younger adults and the challenges in adapting these treatments for older or high-risk patients. He emphasizes careful monitoring for toxicities such as hepatic and neuropsychiatric effects. Balancing Treatment Intensity and Quality of Life With immunotherapy showing strong efficacy, Dr. Litzow anticipates future strategies that reduce chemotherapy exposure, lower toxicity, and improve patient quality of life—especially for older adults or those with comorbidities. Future Directions: AI, Cross-Specialty Collaboration, and Inflammation Research Dr. Litzow shares his optimism about artificial intelligence enhancing trial data analysis and calls for cross-disciplinary collaboration between cancer biologists and clinicians. He also emphasizes the emerging role of inflammation in cancer development, urging broader, non-linear approaches to understanding disease mechanisms. Key Takeaway Dr. Litzow underscores a new era in ALL treatment—where immunotherapy, real-world evidence, and molecular diagnostics intersect to personalize care, extend survival, and minimize toxicity. As clinical science evolves, the focus is shifting from intensifying chemotherapy to optimizing immune-based precision therapies that improve both outcomes and quality of life. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Mark R. Litzow: Hera Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Sassan Mirfakhraee, adult endocrinologist and associate professor at the University of Texas Southwestern Medical Center, shares groundbreaking insights into the management of adrenal insufficiency. At the Endocrine 2025 conference, Dr. Mirfakhraee presented his research on utilizing insulin pumps to deliver hydrocortisone—an innovative off-label approach that is showing promising results for patients who remain symptomatic on oral therapy. He explains how this strategy better mimics the body's natural cortisol rhythm, improves quality of life, and reduces ER visits and hospitalizations for patients with persistent symptoms. Dr. Mirfakhraee also outlines patient selection criteria, training protocols, safety considerations, and the potential for remote monitoring via pump data. This conversation highlights the importance of personalized care in endocrinology, bridging innovation with clinical practice to improve outcomes for patients with challenging conditions. Episode Highlights: New Approach to Adrenal Insufficiency Dr. Mirfakhraee introduces the use of insulin pumps for hydrocortisone infusion, addressing limitations of oral steroids that often fail to fully resolve symptoms. Mimicking Cortisol's Natural Rhythm The pump allows for overnight delivery and tailored boluses, reducing symptoms such as dizziness, nausea, fatigue, and morning crashes that patients often face with oral therapy. Patient Selection and Benefits He outlines which patients may benefit most—those with persistent symptoms, frequent adrenal crises, malabsorption issues, or shift-work challenges—while ensuring other conditions are ruled out. Remote Monitoring and Safety Insulin pumps enable cloud-based data sharing, allowing clinicians to monitor dosing, adjustments, and stress dosing remotely. While generally safe, clinicians must remain vigilant for issues like skin infections or infusion interruptions. Training and Quality of Life Through support from diabetes educators, patients learn how to manage pump settings and troubleshoot. Many report dramatic improvements—returning to work, engaging in family life, and regaining independence. Future Research Needs Dr. Mirfakhraee stresses the need for standardized pump settings, broader data collection, and insurance approval pathways to make this therapy more accessible. Key Takeaway: Insulin pump-based hydrocortisone delivery offers a promising new avenue for patients with adrenal insufficiency who remain symptomatic on oral therapy. By improving quality of life, reducing crises, and allowing for tailored dosing, this approach may represent a paradigm shift in endocrine care. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Sassan Mirfakhraee: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, we welcome Dr. Emily Zboril, a PhD candidate at Virginia Commonwealth University, to discuss her groundbreaking research on ER-positive breast cancer with bone metastasis. Emily sheds light on the unique challenges of treating this condition, the role of the bone microenvironment, and how novel therapies like lazophoxifene may change the landscape of care. She explains how endocrine therapies currently used to block estrogen signaling often worsen bone fragility, leading to osteoporosis, fractures, and increased metastatic growth. Emily's research investigates lazophoxifene, a compound with bone-protective properties that could not only reduce metastatic burden but also improve patients' quality of life. Her work also highlights the potential of new technologies, including spatial transcriptomics and proteomics, to deepen understanding of the bone–cancer interaction and identify biomarkers for treatment response. With ongoing phase III clinical trials, Emily shares her vision for how lazophoxifene and combination therapies may soon offer more effective, less toxic treatment options for patients living with bone metastasis. Episode Highlights: Bone Metastasis Challenges in ER-Positive Breast Cancer Emily outlines why treating bone metastasis is so complex, particularly due to the impact of estrogen signaling on bone health. Promise of Lazophoxifene She introduces lazophoxifene as a bone-protective estrogen receptor modulator, showing strong results in preclinical models and offering a safer alternative to drugs like tamoxifen. New Technology in Cancer Research Cutting-edge approaches such as spatial transcriptomics and proteomics are helping her team map the interactions between cancer and bone cells, advancing precision medicine. Clinical Trials and Future Directions Emily discusses the ongoing ELANE-3 clinical trial and how results may shape the use of lazophoxifene in both metastatic and adjuvant therapy settings. Key Takeaway: Emily Zaboral's research underscores the potential of lazophoxifene to transform treatment for ER-positive breast cancer patients with bone metastasis by protecting bone health, reducing metastatic spread, and improving survival outcomes. With new technologies and clinical trials underway, the future of care for these patients is moving toward safer, more effective therapies. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Emily Zboril: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Alyson K. Myers, endocrinologist and Associate Chair for Faculty Mentoring and Community Engagement at Montefiore in the Bronx, dives into one of the most pressing and underrecognized complications of diabetes: diabetic foot ulcers (DFUs) and the devastating risk of amputations. She discusses the intersection of clinical care, social determinants of health, and healthcare disparities, while also highlighting emerging technologies and multidisciplinary clinic models designed to reduce risks and improve patient outcomes. Drawing on her extensive experience in diabetes management and community engagement, Dr. Myers emphasizes both the urgent need for systemic change and the practical tools clinicians can use today to protect their patients.Episode Highlights High Amputation Risk in Diabetic Foot Ulcers Dr. Myers shares sobering statistics, noting that 44% of patients who present with a diabetic foot ulcer undergo an amputation within five years. This reality highlights the urgency of early screening, prevention, and intervention in diabetes care. She stresses that DFUs are not only medical complications but also markers of systemic inequity and missed opportunities for prevention. The Role of Social Determinants of Health Dr. Myers explores how socioeconomic status, racial disparities, and provider bias profoundly shape patient outcomes. In the Bronx and other underserved areas, patients often face delays in diagnosis, limited access to care, and inconsistent follow-up, all of which contribute to worse outcomes. She emphasizes the importance of addressing these systemic barriers alongside clinical treatment. Innovative Technology for Prevention Emerging tools, such as thermal-sensing mats and sensor-equipped socks, offer promising ways to identify foot ulcers before they progress. These devices can detect subtle temperature changes that indicate early tissue damage, allowing patients and providers to intervene earlier. Dr. Myers highlights the potential of technology to improve adherence and reduce disparities by making self-care more accessible. Building Multidisciplinary DFU Clinics Dr. Myers describes the creation of a multidisciplinary DFU clinic in the Bronx, modeled after programs at institutions like Stanford. By integrating endocrinology, podiatry, vascular surgery, infectious disease, and behavioral health, this model ensures that patients receive comprehensive, coordinated care. She explains how this approach can drastically reduce amputation rates and improve long-term patient outcomes. Patient and Caregiver Education Education remains a cornerstone of DFU prevention. Dr. Myers emphasizes strategies such as ensuring patients wear proper footwear, involving caregivers and family members in diabetes care, and simplifying self-care routines. She points out that community-based education and culturally sensitive approaches are essential for building trust and improving adherence. Advocacy and Policy Change Beyond clinical care, Dr. Myers stresses the importance of advocacy and systemic reform. She calls for insurance coverage expansion for proven therapies, including GLP-1 receptor agonists and PAD (peripheral arterial disease) screenings, which can significantly improve outcomes. Her message is clear: reducing disparities in diabetes care requires action at every level—from the exam room to healthcare policy. Key Takeaway Diabetic foot ulcers are a leading cause of amputation, yet they remain preventable with the right tools and care models. Through early detection technologies, multidisciplinary clinics, culturally sensitive education, and equitable access to therapies, healthcare providers can dramatically improve patient outcomes and close persistent gaps in diabetes care. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Alyson K. Myers:LinkedIn Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Andreas Hochhaus, Professor of Internal Medicine, Hematology, and Oncology at the Comprehensive Cancer Center in Jena, Germany, shares his expertise on the evolution of chronic myeloid leukemia (CML) therapies. He reflects on decades of progress in CML treatment, from interferon to targeted TKIs, and highlights the importance of tolerability, patient-centered care, and innovative trial data shaping the future of CML management. Episode Highlights The Evolution of CML Therapy Dr. Hochhaus outlines the transformation of CML treatment, from interferon to imatinib, and the development of second- and third-generation TKIs. He emphasizes advances in efficacy while acknowledging the persistent challenge of drug resistance. Managing Tolerability and Side Effects Toxicities such as cardiovascular, hepatic, and renal complications remain key concerns. Dr. Hochhaus discusses how improving tolerability is central to optimizing patient quality of life. Enliven-01 Trial He highlights the unique pharmacologic profile of Enliven-01, with fewer off-target effects and encouraging safety data, underscoring its potential as a novel therapeutic option. ASCIMINIB as a New Standard Comparing ASCIMINIB with nilotinib, Dr. Hochhaus explains its superior tolerability and efficacy, positioning it as a game-changer in frontline CML therapy. Patient-Centered Care and Future Directions Dr. Hochhaus stresses the importance of shared decision-making, molecular monitoring, and pathways to treatment-free remission, while also pointing to challenges such as additional gene mutations and resistance mechanisms. Key Takeaway The future of CML treatment lies in balancing efficacy, safety, and patient quality of life. With emerging therapies like Enliven-01 and ASCIMINIB, clinicians can provide more personalized and effective care while expanding opportunities for treatment-free remission. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Andreas Hochhaus LinkedIn Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Eleonora Teplinksy, a breast and gynecologic medical oncologist at Valley Health System and clinical assistant professor at the Icahn School of Medicine at Mount Sinai, shares key updates from the ASCO annual meeting. She discusses transformative clinical trials that are reshaping the landscape of metastatic breast cancer treatment across subtypes including hormone receptor-positive, HER2-positive, and triple-negative breast cancer. Dr. Teplinksy highlights the promise of early mutation detection, the potential of antibody-drug conjugates, and the power of liquid biopsies. She also addresses pressing concerns around clinical trial diversity, treatment access, and the need for multidisciplinary care. Episode Highlights: Early Detection in HR+ Breast Cancer: The SERENA-6 Trial The SERENA-6 trial investigates whether switching to camizestrant—an oral SERD—upon early ESR1 mutation detection via liquid biopsy (before radiographic progression) improves progression-free survival. The study showed a 56% reduction in disease progression risk. However, issues around FDA approval, cost, testing frequency, and racial representation remain key concerns. Advancing Triple-Negative Breast Cancer Care: ASCENT-04 The ASCENT-04 trial evaluates sacituzumab govitecan plus pembrolizumab vs. standard chemo-immunotherapy in PD-L1+ patients. Results revealed improved PFS (7.8 to 11.2 months), showing promise for first-line triple-negative treatment, though insurance coverage may delay clinical implementation. HER2+ Breast Cancer Innovation: DESTINY-Breast09 This trial demonstrated that combining T-DXd with pertuzumab improved PFS from 26.9 to 40 months, suggesting a new standard for HER2+ metastatic breast cancer. Still, side effects like interstitial lung disease and lack of clarity on endocrine therapy integration must be addressed. Real-World Barriers: Cost, Toxicity, and Care Access Dr. Teplinksy emphasizes challenges patients face—from time toxicity to insurance denials—and calls for thoughtful side-effect management and patient-centered treatment planning. Multidisciplinary Collaboration and Future of AI in Oncology She underlines the role of interdisciplinary care and the need to bridge gaps across specialties. With AI and machine learning emerging, Dr. Teplinksy envisions more tailored treatments driven by biomarkers and real-world insights. Key Takeaway Dr. Teplinksy stresses the importance of early intervention, clinical trial equity, and multidisciplinary care in improving breast cancer outcomes. As the field embraces antibody-drug conjugates and AI-driven personalization, collaboration and access must evolve in step. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Eleonora Teplinksy: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Ashley Sumrall, a neuro-oncologist and Section Chief at Atrium Health Levine Cancer Institute, shares groundbreaking insights into the treatment of diffuse midline gliomas with the H3K27M mutation. Dr. Sumrall presents data from pediatric and adult studies using Dordaviprone (ONC201), highlighting its promising response rates and tolerability. She also discusses the evolving role of AI in neuro-oncology, the value of multidisciplinary care, and the need for advocacy in biomarker access and healthcare policy. Episode Highlights: Advancements in Treating Rare Brain Tumors Dr. Sumrall introduces updated clinical findings on Dordaviprone for diffuse midline gliomas, a rare and aggressive brain tumor affecting children and young adults. The combined adult and pediatric studies showed a 20% overall response rate and minimal serious side effects, offering a new sense of hope in an area with limited treatment options. Pediatric-Adult Trial Integration She explains the rationale for combining data from adult and pediatric studies due to the rarity of the disease and evolving definitions of pediatric age groups. This integrated approach offers valuable insights into treatment effectiveness across the age spectrum. Promise of AI in Neuro-Oncology Dr. Sumrall emphasizes how machine learning and AI tools like OpenEvidence and ChatGPT can streamline imaging analysis, assist in clinical trial design, and improve diagnostic efficiency. She foresees AI as a co-pilot in tumor boards and day-to-day clinical decisions. Well-Tolerated Therapy and Quality of Life Unlike many cancer treatments, ONC201 demonstrates a low side effect profile, with zero serious adverse events reported. This is especially significant for brain tumor patients who often face limited options beyond surgery and radiation. Biomarkers and Access Challenges She highlights the importance of biomarker testing in classifying tumors and guiding therapy. However, she warns of ongoing disparities in access due to high costs and limited insurance coverage, particularly in community care settings. Advocacy for Research Funding and Access Dr. Sumrall underscores the role of physician and patient advocacy in preserving NIH and NCI funding, expanding access to biomarker profiling, and supporting legislation to streamline patient care. Collaborative Oncology Models She describes her work in multidisciplinary tumor boards and genetic predisposition clinics, where oncologists, geneticists, and endocrinologists jointly tailor proactive care plans—an approach she believes should be the gold standard in oncology. Key Takeaway Dr. Sumrall reinforces that innovation in rare brain tumor treatment must be matched by advocacy, access to biomarker testing, and the adoption of AI-powered tools. The progress with ONC201 offers hope not just in extending life but also in improving the quality of life for patients once left without options. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Ashley Sumrall: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Karine Tawagi, a genitourinary medical oncologist at the University of Illinois in Chicago, shares cutting-edge updates from ASCO 2024 related to bladder, prostate, and kidney cancers. Dr. Tawagi explores the clinical implications of circulating tumor DNA (CT DNA), discusses evolving bladder preservation strategies, and addresses the expanding role of PARP inhibitors in prostate cancer. She also emphasizes the importance of equitable access to new therapies and multidisciplinary collaboration in cancer care. Episode Highlights Advances in Bladder Cancer Management Dr. Tawagi reviews the Niagara study, which integrates dervalumab immunotherapy with standard cisplatin-based chemotherapy. This new regimen has become a standard of care for cisplatin-eligible patients with muscle-invasive bladder cancer. She also discusses ongoing trials and the promise of bladder preservation, especially for patients concerned about quality of life post-cystectomy. The Power of CT DNA in Personalizing Treatment CT DNA is emerging as a powerful prognostic tool in bladder cancer, with potential use in escalating or de-escalating treatments based on molecular response. Dr. Tawagi discusses its role in both neoadjuvant and metastatic settings, including trials like the MODERN study. PARP Inhibitors in Prostate Cancer For prostate cancer patients with homologous recombination repair mutations—especially BRCA1/2—Dr. Tawagi highlights the role of PARP inhibitors such as niraparib and the Amplitude trial's results in the castration-sensitive setting. She discusses the ongoing debate around sequencing, survival outcomes, and access. Kidney Cancer and Immunotherapy An update from the Keynote 564 trial shows continued benefit of adjuvant pembrolizumab for high-risk localized kidney cancer. Dr. Tawagi underscores the importance of patient counseling using risk calculators and timely referral to oncology after nephrectomy. The Importance of Multidisciplinary Care Dr. Tawagi emphasizes collaboration among urologists, radiation oncologists, medical oncologists, and other specialties to deliver optimal, patient-centered care. She calls for increased awareness of trial updates and improved access to novel therapies across diverse populations. Key Takeaway Dr. Tawagi emphasizes that the future of genitourinary oncology lies in individualized treatment informed by biomarkers like CT DNA, equitable access to novel therapies, and strong multidisciplinary collaboration to enhance outcomes and preserve quality of life. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Karine Tawagi: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, we welcome Peixuan Zheng, an exercise scientist at the University of Illinois Chicago, who shares her research on using step-based physical activity metrics to assess and enhance the daily function of individuals with multiple sclerosis (MS). Peixuan discusses how wearable technology and new step-counting methods—like peak cadence—can provide more accurate insights into patients' real-world mobility compared to traditional clinical assessments. She also dives into her intervention programs combining aerobic and resistance training to support cognitive and physical function in older adults with MS, highlighting improvements in learning, memory, and ambulation. The conversation explores the promise of personalized, at-home exercise prescriptions, the role of motivation in long-term adherence, and how machine learning and advanced wearable sensors could further revolutionize MS care. Episode Highlights Real-World Walking Metrics for MS Patients Peixuan introduces the use of wearable sensors to measure "step-based metrics" like daily steps and peak cadence, capturing real-life walking performance more accurately than traditional lab tests. Reliability of Step-Based Metrics Validated over a six-month period, step-based data showed consistency across time, making it a reliable alternative for tracking changes in mobility outside clinical settings. Home-Based Exercise Interventions Zheng shares results from a 16-week home-based program combining aerobic and resistance exercises aimed at improving cognition and mobility in older adults with MS. Impact on Cognitive Function The intervention led to improved cognitive processing speed and learning/memory outcomes, measured by the BICAMS battery. Role of Motivation and Personal Goals Understanding patient motivations—like walking better or engaging in family activities—helps tailor exercise plans, boosting adherence and long-term outcomes. Machine Learning and Future Applications Zheng sees a future where AI and wearable technology help generate personalized exercise prescriptions based on real-time physiological and movement data. Key Takeaway Peixuan Zheng's research shows that real-world step-based metrics and personalized, home-based exercise programs offer promising ways to monitor and improve mobility and cognition in people with MS. Her work supports a future of MS care grounded in precision, motivation, and multidisciplinary collaboration. Resources Website: https://mdnewsline.com Newsletter: Subscribe to Updates Connect with Peixuan Zheng: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Alice Edward, a pediatric and adult neurologist and neuroimmunology specialist, explores the complex landscape of diagnosing and managing multiple sclerosis (MS) in children. She highlights the critical differences between pediatric and adult MS, including symptom presentation, diagnostic criteria, and treatment strategies. Dr. Edward also delves into the impact of hormonal changes, pregnancy planning, and the challenges of transitioning care from pediatric to adult neurology services. Episode Highlights Pediatric vs. Adult MS Presentation Dr. Edward discusses how children often present with more inflammatory forms of MS and experience more frequent relapses. She emphasizes the brain's plasticity in younger patients, which can sometimes lead to better recovery. Diagnostic Criteria and Challenges She explains the pediatric-specific McDonald criteria and the importance of excluding alternative diagnoses like encephalitis, meningitis, or genetic disorders due to the rarity of pediatric MS. Red Flags and Misdiagnoses Dr. Edward points out clinical signs that may suggest non-MS demyelinating conditions and stresses the importance of early MRI access and parental advocacy. High-Efficacy First-Line Therapy Unlike the step-up approach in adults, pediatric MS often requires starting with high-efficacy disease-modifying therapies (DMTs) to control aggressive inflammation. She explains why escalation therapy is not favored in children. Hormonal and Life Stage Considerations Puberty, pregnancy, and aging play critical roles in MS management. Dr. Edward reviews the latest data on DMT use during pregnancy and postpartum periods, emphasizing preventive planning. The Transition to Adult Care Dr. Edward outlines the need for smoother transitional care and continuity between pediatric and adult MS services. She shares her vision for building a lifelong care model. Cognitive Outcomes and Disease Progression Children diagnosed with MS may face more significant cognitive challenges over time due to longer disease duration. Early and aggressive therapy can mitigate long-term deficits. Key Takeaway Pediatric MS is rare but more inflammatory and demands early, aggressive treatment. Tailoring care throughout a patient's lifespan—including puberty, pregnancy, and transition to adult neurology—is vital to optimizing outcomes and preventing disability. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Alice Edward: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Michael Robers, a neurologist and multiple sclerosis (MS) specialist at Barrow Neurological Institute in Phoenix, Arizona, shares groundbreaking research on the intersection of hypertension and MS. He highlights the high prevalence of undiagnosed hypertension among MS patients and its association with worse physical disability. Dr. Robers also explores systemic care gaps and advocates for a more integrated, whole-person approach to MS care—emphasizing the role of MS specialists in detecting comorbidities early. Episode Highlights: Understanding MS Health Disparities Dr. Robers discusses how Black, Hispanic, and Indigenous Americans face worse MS outcomes compared to white Americans. Contributing factors include underdiagnosis, delayed care, and insufficient screening, particularly for comorbid conditions like hypertension. The Hidden Impact of Hypertension on MS Disability His research reveals that MS patients with uncontrolled hypertension are over twice as likely to require ambulatory aids. Notably, 27% of patients met hypertension criteria via vital signs, while only 7% had formal diagnoses—highlighting a major care gap. Why Awareness Matters Women, younger patients, and those with borderline high blood pressure are more likely to be unaware of their hypertension status. Dr. Robers urges MS specialists to ask simple screening questions and refer patients to primary care, even if they don't manage blood pressure themselves. Collaborating Across Specialties Dr. Robers discusses the growing need for inter-specialty collaboration in chronic disease care, emphasizing how subspecialists like neurologists can identify issues traditionally addressed in primary care. The Path Forward in MS Care He calls for a broader focus on long-term wellness for MS patients—including screening for common but impactful comorbidities like hypertension. Future research may reveal whether proactive control of blood pressure can reduce long-term disability in MS. Key Takeaway: Undiagnosed hypertension is a modifiable risk factor in MS care. MS providers can help bridge a major care gap by screening for high blood pressure—especially in young, female, and underserved patients—to prevent worsening disability and promote holistic patient health. Resources Link: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Michael Robers: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Olivia Wills and Karen Zoczak—accredited practicing dietitians and researchers from Australia—explore the evolving role of dietetics in multiple sclerosis (MS) care. Recorded at a global MS conference, the discussion spotlights the importance of individualized dietary support as part of a comprehensive, multidisciplinary care plan. Dr. Wills and Ms. Zoczak share insights from their latest research and real-world clinical experiences, highlighting how nutrition can improve symptom management, metabolic health, and overall quality of life in people living with MS. Episode Highlights: The Expanding Role of Dietitians in MS Care Dr. Wills and Karen Zoczak discuss how dietetics has grown from a peripheral topic to a respected tool in MS treatment. They emphasize that while diet is not a cure, it is a powerful strategy for improving outcomes and quality of life. Understanding Popular MS Diet Trends The duo unpacks common MS-specific diets like the Swank, Wahl's, OMS, and Best Bet diets—exploring their promises, pitfalls, and nutritional risks when compared to official dietary guidelines. Introducing the MS Diet Risk Tool Karen introduces her soon-to-be-published tool that helps compare various dietary patterns with national dietary guidelines to identify potential nutritional deficiencies and risks. Clinical Red Flags and the Importance of Individualized Nutrition From micronutrient deficiencies (like B12) to fiber intake, the dietitians explain how personalized dietary care can resolve symptoms like neuropathy, constipation, and fatigue while supporting broader brain and metabolic health. Real Patient Success Stories Olivia shares powerful case studies, including a patient who reversed type 2 diabetes markers through nutrition and another who regained mobility and health after recovering from severe malnutrition with dietitian support. Nutrition, Brain Health, and the Microbiome The conversation explores emerging research on the gut and oral microbiome, metabolic comorbidities, and how personalized nutrition could shape lifelong brain health in MS patients. Advocating for the Multidisciplinary Model The episode closes with a call to action for clinicians: refer patients to dietitians early and often to maximize outcomes, reduce risk, and reinforce a unified care strategy. Key Takeaway Nutrition is a critical, evidence-based component of MS care. While it doesn't replace pharmacological treatment, dietetics offers a powerful way to manage symptoms, reduce comorbidities, and improve quality of life—especially when integrated into a comprehensive, multidisciplinary approach. Resources & Links: Website: MD Newsline Newsletter: Subscribe Connect with Dr. Olivia Wills: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Sarimar Agosto Salgado, Oncologic Endocrinologist at Moffitt Cancer Center, shares insights from a panel discussion at the AACE 2025 conference on the complexities of advanced thyroid cancer. She explores case-based approaches to recurrent, radioactive iodine-refractory disease and introduces the evolving strategy of re-differentiation therapy—a promising method for resensitizing tumors to radioactive iodine. Dr. Salgado also highlights real-world challenges including diagnostic errors, late referrals, and the need for greater access to multidisciplinary care. Episode Highlights Understanding Radioactive Iodine-Refractory Disease Dr. Salgado explains that a subset of thyroid cancer patients no longer respond to radioactive iodine due to disease progression. For these patients, careful monitoring, local therapies like SBRT, or systemic treatments become necessary depending on the tumor's growth and location. Re-differentiation Therapy Explained She introduces re-differentiation—a technique using short-term targeted therapy (e.g., BRAF inhibitors) to restore the tumor's ability to uptake radioactive iodine. This allows for additional rounds of treatment and may delay or reduce the need for long-term systemic therapy. The Role of Real-World Data and Registries Because prospective clinical trials remain limited, Dr. Salgado advocates for collecting data through real-world registries and academic collaborations. These efforts may help define optimal timing, predictive markers, and response indicators for re-differentiation therapy. Challenges in Diagnosis and Timely Referral Dr. Salgado reflects on misdiagnosed cases, including rare thyroid variants confused with neuroendocrine tumors. She emphasizes the importance of early referral to expert centers before treatment limits available options. Access and Equity in Advanced Thyroid Cancer Many patients lack access to high-volume thyroid teams, leading to missed opportunities. Dr. Salgado urges clinicians to prioritize expert pathology review, molecular testing, and full-neck imaging to avoid delays in diagnosis and care. Key Takeaway Advanced thyroid cancer is complex and often underestimated. Early referral, precision strategies like re-differentiation, and equitable access to expert teams are critical to improving outcomes and expanding hope for patients with this challenging disease. Resources & Links: Website: MD Newsline Newsletter: Subscribe Connect with Dr. Sarimar Agosto Salgado: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Omolara G. Adeniran, an endocrinologist practicing in Florida, shares her frontline experience addressing the complex realities of diabetes management, technology hesitancy, and healthcare disparities. Drawing on insights from the American Association of Clinical Endocrinology (AACE) conference, Dr. Adeniran discusses lipodystrophy, CGM technology, and how to navigate social determinants of health in real-world patient care. Episode Highlights: Recognizing Lipodystrophy and Treatment Overlap Dr. Adeniran highlights a key learning from the conference—a lecture on differentiating lipodystrophy from Cushing syndrome, a diagnostic challenge due to overlapping features. She shares how improved understanding of this rare condition can lead to significant improvement in comorbidities like severe insulin resistance and hypertriglyceridemia once correctly identified and treated. Breaking Down Technology Barriers with CGMs Continuous glucose monitoring (CGM) remains underutilized due to patient fears and insurance limitations. Dr. Adeniran explains her approach: providing demo models, offering trial periods, and giving reassurance about data privacy to help patients gain comfort with technology and improve their diabetes self-management. Navigating Insurance, Food Access, and Cultural Habits Insurance coverage, food deserts, and cultural food practices remain major obstacles. Dr. Adeniran shares strategies for working with patients in lower-resource settings, including promoting portion control, pragmatic dietary substitutions, and encouraging family involvement in nutrition and care. Engaging Patients in Shared Decision-Making From discussing A1C levels to blood pressure trends, Dr. Adeniran emphasizes making data relatable. She walks patients through lab comparisons over time and links clinical numbers to how they feel—helping them take ownership of their health. Emotional support and patient storytelling help reinforce behavior change. The Power of Listening and Small Steps According to Dr. Adeniran, patient progress starts with empathetic listening. She urges clinicians to hear the small clues that lead to big breakthroughs. Whether managing obesity, thyroid conditions, or diabetes, she believes in celebrating small wins and meeting patients where they are—both medically and personally. Key Takeaway: Effective endocrine care hinges on trust, technology, and tailored solutions. From CGM adoption to dietary adjustments, empowering patients with education and empathy is key to closing gaps and improving outcomes. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Omolara Adeniran: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Kamrun Naher, an endocrinologist based in Brooklyn, shares two compelling case studies that highlight how seemingly psychiatric symptoms and subtle complaints can conceal serious endocrine disorders. She recounts a rare case where suicidal behavior and insomnia led to the discovery of a neuroendocrine tumor in the pancreas, as well as a cluster of unexpected diagnoses of pheochromocytoma—a rare tumor of the adrenal glands. Dr. Naher underscores the need for multidisciplinary collaboration, greater awareness among providers, and earlier patient education to prevent delayed diagnoses and potentially life-threatening complications. Episode Highlights: Unmasking a Neuroendocrine Tumor A patient initially treated for psychiatric symptoms—including depression and insomnia—was ultimately found to have hypoglycemia-induced neuroendocrine tumor in the pancreas. Dr. Naher explains how a cascade of symptoms and an incidental CT scan led to a life-changing diagnosis and surgical treatment. Mental Health vs. Medical Misdiagnosis This case prompts a broader discussion on the importance of not attributing all behavioral health crises to psychiatric origins. Symptoms like insomnia and depression may sometimes be manifestations of metabolic or endocrine issues such as insulin-producing tumors. Pheochromocytoma in the Real World Dr. Naher reflects on a series of pheochromocytoma cases she diagnosed within one month—despite never seeing any during her fellowship. The episodic symptoms—palpitations, sweating, and chest pain—were often dismissed as normal or unrelated. These cases show how pattern recognition and detailed patient questioning can make a diagnostic difference. Preventing Missed Diagnoses Through Simple Questions Dr. Naher advocates for providers to ask patients: "What feels unusual or not normal to you?" This one question, she argues, could bring hidden symptoms to light and lead to earlier detection of rare but serious conditions. Data Collection and Global Awareness She also shares her vision for creating a global hub for rare case data, aiming to gather insight from providers worldwide to better identify trends, recognize genetic syndromes like MEN1, and promote broader awareness. Key Takeaway Not every psychiatric symptom is psychiatric in origin. Early intervention, cross-disciplinary collaboration, and asking the right questions can uncover life-threatening endocrine disorders—and change the course of care. Resources & Links Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Kamrun Naher: Here Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Elias Jabbour, Professor of Medicine at MD Anderson Cancer Center, shares groundbreaking insights into the evolving treatment landscape of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). He discusses the transformative role of tyrosine kinase inhibitors (TKIs), strategies to achieve treatment-free remission, and how genetic testing, CAR-T therapy, and monoclonal antibodies are reshaping frontline and relapsed leukemia management. Episode Highlights: The TKI Revolution in CML Dr. Jabbour recounts how TKIs have shifted CML from a fatal disease to one with normal life expectancy, even allowing for treatment discontinuation in select patients after prolonged deep molecular remission. He explains how monitoring and response milestones guide therapy and when mutation testing is necessary. Understanding Resistance and Personalized Care Resistance to TKIs is rare when patients are compliant. Dr. Jabbour outlines how NGS is used to detect kinase domain mutations and guide next-line therapy, particularly in BCR-ABL-independent resistance. He also shares why genomic profiling isn't yet used for frontline CML treatment but may become more relevant in advanced disease. Integrating Immunotherapy in ALL In adult ALL, Dr. Jabbour explains how immunotherapy and TKIs are reducing the need for chemotherapy and transplantation, improving both survival and quality of life. He discusses how CAR-T therapy may move to the frontline setting to shorten treatment duration and potentially eliminate the need for allogeneic transplant. AML: Moving Toward Targeted Frontline Therapy Dr. Jabbour outlines how FLT3, IDH, and menin inhibitors are improving outcomes in AML, especially when combined with hypomethylating agents and venetoclax. He stresses the importance of minimal residual disease (MRD) monitoring to tailor therapy and reduce overtreatment. Overcoming Barriers and Promoting Access He reflects on challenges like drug cost, limited access to specialized care, and clinical trial barriers such as travel and housing. Dr. Jabbour calls for simplified regimens that can be delivered anywhere, so that all patients—not just those at top centers—can benefit from the latest innovations. Key Takeaway: With the right combinations of targeted therapies, immunotherapies, and patient-specific monitoring, many leukemias—especially CML and ALL—are becoming manageable or even curable. But equitable access, affordability, and ongoing collaboration are essential to truly transform care worldwide. Resources: Website: https://mdnewsline.com Newsletter: https://mdnewsline.com/subscribe Connect with Dr. Elias Jabbour: MD Anderson Profile Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Jamie Almandoz, Associate Professor at UT Southwestern Medical Center and Medical Director of the Weight Wellness and Obesity Medicine Program, discusses the evolving science of post-bariatric weight management, the rising use of GLP-1 medications, and the role of multidisciplinary care in treating obesity as a chronic illness. He shares practical insights into weight regain after bariatric surgery, how medications can support long-term outcomes, and the importance of nutrition, mental health, and individualized care. Episode Highlights Understanding Post-Bariatric Weight Regain Dr. Almandoz explains why obesity is not cured by surgery and how weight regain—up to 40% on average—is common due to metabolic adaptation, hormonal shifts, and anatomical changes. He emphasizes the need to redefine success by health improvement, not just weight loss. The Role of GLP-1 and Incretin Therapies GLP-1 receptor agonists and other medications have become powerful tools in obesity management. Dr. Almandoz discusses their potential to support both pre- and post-surgical patients, how they affect hunger and calorie intake, and their limitations, including malnutrition risks and bone density concerns. Nutrition and Long-Term Risks Dr. Almandoz warns of malnutrition and lean mass loss among patients using potent weight-loss medications, especially when combined with low-quality diets. He highlights the need for dietary counseling, micronutrient screening, and follow-up—particularly for postmenopausal women and those with chronic illness. Multidisciplinary Care and Mental Health From registered dietitians to primary care providers, a coordinated care team is key. Dr. Almandoz advocates for mental health screening, SMART goal-setting, and destigmatized obesity treatment, recognizing that each patient's health goals and progress vary. Personalized and Precision Medicine in Obesity As newer medications target different biological pathways, Dr. Almandoz calls for a precision approach to obesity care—matching treatment combinations to the individual's physiology, comorbidities, and life context, rather than applying a one-size-fits-all model. Key Takeaway Obesity is a chronic disease requiring lifelong care. Neither surgery nor medication alone is curative—personalized, multidisciplinary strategies that address nutrition, mental health, and physical health are essential to improving outcomes and quality of life. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Jamie Almandoz: LinkedIn Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Beth Malow, a professor of neurology and pediatrics at Vanderbilt University Medical Center, shares her unique perspective on the intersections of climate change, sleep health, and brain health. She explores how environmental factors like air pollution and extreme heat can worsen conditions such as autism, dementia, stroke, and sleep disorders, while also discussing the importance of interdisciplinary research, science communication, and patient advocacy in mitigating these risks. Episode Highlights: The Role of Sleep in Brain Health Dr. Malow describes sleep as the brain's "reset button," explaining how sleep deprivation can impair emotional regulation, worsen neurological conditions, and weaken brain connectivity. She emphasizes behavioral and medical strategies to improve sleep, particularly in patients with epilepsy, autism, and neurodivergent conditions. Climate Change and Neurological Risk Air pollutants like PM2.5, nitrogen dioxide, and ozone are now linked to increased risks of stroke, dementia, and autism, particularly when exposure occurs early in life. Dr. Malow highlights the neurological danger of environmental toxins crossing the blood-brain barrier and triggering neuroinflammation or epigenetic changes. Extreme Heat and Sleep Disruption Rising temperatures from climate change not only reduce sleep quality, but also exacerbate health risks for vulnerable populations, including patients with neurological disorders or those taking medications that impair thermoregulation. Dr. Malow calls for clinicians to consider environmental exposure in patient assessments and education. The Power of Advocacy and Interdisciplinary Collaboration From medical societies to legislative outreach, Dr. Malow advocates for collaboration across specialties and sectors to tackle the public health crisis of climate-related illness. She urges healthcare professionals to take small, meaningful actions—from patient education to environmental assessments—and stresses the importance of science communication in amplifying this message. Turning Risk Into Opportunity Rather than viewing climate change through a lens of fear, Dr. Malow encourages clinicians to see it as a catalyst for innovation. By addressing these risks head-on and working together across silos, the healthcare community can drive forward transformative, patient-centered solutions. Key Takeaway: Environmental factors like air pollution and extreme heat have significant impacts on brain health and sleep. With interdisciplinary collaboration and patient-centered advocacy, clinicians can play a critical role in addressing these challenges and creating opportunities for improved health outcomes. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Beth Malow: https://www.vanderbilthealth.com/doctors/malow-beth Hosted on Acast. See acast.com/privacy for more information.

In this episode of MD Newsline, Dr. Jennifer Vermillion, assistant professor of neurology and pediatrics at the University of Rochester, shares her insights into pediatric movement disorders and rare neurodegenerative diseases, including Tourette syndrome and Batten disease (NCLs). She discusses how early diagnosis, genetic research, and advances in treatment—including gene therapy—are reshaping outcomes for children with these conditions. Dr. Vermillion also emphasizes the role of natural history studies, clinical trial design, and equitable access in improving care for patients and families. Episode Highlights: Recognizing Movement Disorders in Children Dr. Vermillion explains the spectrum of pediatric movement disorders, from benign behaviors like infant shuddering to chronic conditions like Tourette syndrome. She underscores the importance of understanding both the neurological and psychiatric aspects of these conditions, especially in children who also experience anxiety, OCD, or behavioral challenges. Tourette Syndrome: What We Know Now Tourette syndrome is often diagnosed in early childhood and may improve in adulthood for some. While there is no cure, new medications with fewer side effects have replaced older drugs like haloperidol. Dr. Vermillion highlights how improved understanding of brain circuitry and dopamine regulation is advancing treatment options. Batten Disease and the Role of Natural History Studies As a specialist in neuronal ceroid lipofuscinoses (NCLs), also known as Batten diseases, Dr. Vermillion explains the genetic basis of these rare disorders and the symptoms—seizures, cognitive decline, vision loss, and behavioral changes. She details her work on 20+ years of natural history data collection to support more effective trial design and the evaluation of emerging gene therapies. Barriers to Diagnosis and Access to Treatment Early diagnosis is crucial—especially when gene-based therapies may halt disease progression. Dr. Vermillion emphasizes the importance of newborn screening, standardized data collection across research centers, and the ethical challenges of delayed or denied insurance coverage for costly but life-altering treatments. The Future of Pediatric Rare Disease Care Dr. Vermillion is optimistic about the rapid advancements in rare disease therapy, particularly gene therapy and precision medicine. However, she calls for stronger advocacy, improved measurement tools, and more equitable systems to ensure all patients benefit from these scientific breakthroughs. Key Takeaway: With expanding access to genetic testing and emerging gene-based therapies, the landscape for pediatric movement and neurodegenerative disorders is evolving rapidly—highlighting the need for early diagnosis, collaborative research, and equitable access to care. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Jennifer Vermillion: https://www.urmc.rochester.edu/people/112360756-jennifer-a-vermilion Hosted on Acast. See acast.com/privacy for more information.